Tumors or cancer located in bone tissue or specific BONES.
A specialized CONNECTIVE TISSUE that is the main constituent of the SKELETON. The principle cellular component of bone is comprised of OSTEOBLASTS; OSTEOCYTES; and OSTEOCLASTS, while FIBRILLAR COLLAGENS and hydroxyapatite crystals form the BONE MATRIX.
The continuous turnover of BONE MATRIX and mineral that involves first an increase in BONE RESORPTION (osteoclastic activity) and later, reactive BONE FORMATION (osteoblastic activity). The process of bone remodeling takes place in the adult skeleton at discrete foci. The process ensures the mechanical integrity of the skeleton throughout life and plays an important role in calcium HOMEOSTASIS. An imbalance in the regulation of bone remodeling's two contrasting events, bone resorption and bone formation, results in many of the metabolic bone diseases, such as OSTEOPOROSIS.
The amount of mineral per square centimeter of BONE. This is the definition used in clinical practice. Actual bone density would be expressed in grams per milliliter. It is most frequently measured by X-RAY ABSORPTIOMETRY or TOMOGRAPHY, X RAY COMPUTED. Bone density is an important predictor for OSTEOPOROSIS.
Bone loss due to osteoclastic activity.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells.
The growth and development of bones from fetus to adult. It includes two principal mechanisms of bone growth: growth in length of long bones at the epiphyseal cartilages and growth in thickness by depositing new bone (OSTEOGENESIS) with the actions of OSTEOBLASTS and OSTEOCLASTS.
Diseases of BONES.
Renewal or repair of lost bone tissue. It excludes BONY CALLUS formed after BONE FRACTURES but not yet replaced by hard bone.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Extracellular substance of bone tissue consisting of COLLAGEN fibers, ground substance, and inorganic crystalline minerals and salts.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Organic compounds which contain P-C-P bonds, where P stands for phosphonates or phosphonic acids. These compounds affect calcium metabolism. They inhibit ectopic calcification and slow down bone resorption and bone turnover. Technetium complexes of diphosphonates have been used successfully as bone scanning agents.
Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.
The administrative process of discharging the patient, alive or dead, from hospitals or other health facilities.

Relative efficacy of 32P and 89Sr in palliation in skeletal metastases. (1/5419)

32p and 89Sr have been shown to produce significant pain relief in patients with skeletal metastases from advanced cancer. Clinically significant pancytopenia has not been reported in doses up to 12 mCi (444 MBq) of either radionuclide. To date, no reports comparing the relative efficacy and toxicity of the two radionuclides in comparable patient populations have been available. Although a cure has not been reported, both treatments have achieved substantial pain relief. However, several studies have used semiquantitative measures such as "slight," "fair," "partial" and "dramatic" responses, which lend themselves to subjective bias. This report examines the responses to treatment with 32P or 89Sr by attempting a quantification of pain relief and quality of life using the patients as their own controls and compares toxicity in terms of hematological parameters. METHODS: Thirty-one patients with skeletal metastases were treated for pain relief with either 32P (16 patients) or 89Sr (15 patients). Inclusion criteria were pain from bone scan-positive sites above a subjective score of 5 of 10 despite analgesic therapy with narcotic or non-narcotic medication, limitation of movement related to the performance of routine daily activity and a predicted life expectancy of at least 4 mo. The patients had not had chemotherapy or radiotherapy during the previous 6 wk and had normal serum creatinine, white cell and platelet counts. 32P was given orally as a 12 mCi dose, and 89Sr was given intravenously as a 4 mCi (148 MBq) dose. The patients were monitored for 4 mo. RESULTS: Complete absence of pain was seen in 7 of 16 patients who were given 32P and in 7 of 15 patients who were given 89Sr. Pain scores fell by at least 50% of the pretreatment score in 14 of 16 patients who were given 32P and 14 of 15 patients who were given 89Sr. Mean duration of pain relief was 9.6 wk with 32P and 10 wk with 89Sr. Analgesic scores fell along with the drop in pain scores. A fall in total white cell, absolute granulocyte and platelet counts occurred in all patients. Subnormal values of white cells and platelets were seen in 5 and 7 patients, respectively, with 32P, and in 0 and 4 patients, respectively, after 89Sr therapy. The decrease in platelet count (but not absolute granulocyte count) was statistically significant when 32P patients were compared with 89Sr patients. However, in no instance did the fall in blood counts require treatment. Absolute granulocyte counts did not fall below 1000 in any patient. There was no significant difference between the two treatments in terms of either efficacy or toxicity. CONCLUSION: No justification has been found in this study for the recommendation of 89Sr over the considerably less expensive oral 32P for the palliation of skeletal pain from metastases of advanced cancer.  (+info)

A fluorescent orthotopic bone metastasis model of human prostate cancer. (2/5419)

Here, we report a fluorescent spontaneous bone metastatic model of human prostate cancer developed by surgical orthotopic implantation of green fluorescent protein (GFP)-expressing prostate cancer tissue. Human prostate cancer PC-3 cells were transduced with the pLEIN expression retroviral vector containing the enhanced GFP and neomycin resistance genes. Stable GFP high-expression PC-3 clones were selected in vitro with G418, which were then combined and injected s.c. in nude mice. For metastasis studies, fragments of a single highly fluorescent s.c. growing tumor were implanted by surgical orthotopic implantation in the prostate of a series of nude mice. Subsequent micrometastases and metastases were visualized by GFP fluorescence throughout the skeleton, including the skull, rib, pelvis, femur, and tibia The central nervous system, including the brain and spinal cord, was also involved with tumor, as visualized by GFP fluorescence. Systemic organs, including the lung, plural membrane, liver, kidney, and adrenal gland, also had fluorescent metastases. The metastasis pattern in this model reflects the bone and other metastatic sites of human prostate cancer. Thus, this model should be very useful for the study and development of treatment for metastatic androgen-independent prostate cancer.  (+info)

Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. (3/5419)

We determined the effects of the potent bisphosphonate ibandronate in a murine model of human myeloma bone disease. In this model, bone lesions typical of the human disease develop in mice following inoculation of myeloma cells via the tail vein. Treatment with ibandronate (4 micrograms per mouse per day) significantly reduced the occurrence of osteolytic bone lesions in myeloma-bearing mice. However, ibandronate did not prevent the mice from developing hindlimb paralysis and did not produce a detectable effect on survival. There was no significant effect of ibandronate on total myeloma cell burden, as assessed by morphometric measurements of myeloma cells in the bone marrow, liver, and spleen, or by measurement of serum IgG2b levels. These results support clinical findings that bisphosphonates may be useful for the treatment of myeloma-associated bone destruction, but suggest that other therapies are also required to reduce tumor growth.  (+info)

Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. (4/5419)

Bombesin-like peptides such as gastrin-releasing peptide (GRP) have been shown to play a role in cancer as autocrine growth factors that stimulate tumor growth through specific receptors. To search for potential clinical indications for GRP analogues, it is important to identify human tumor types expressing sufficient amounts of the respective receptors. In the present study, we have evaluated the expression of GRP receptors in human nonneoplastic and neoplastic prostate tissues using in vitro receptor autoradiography on tissue sections with 125I-Tyr4-bombesin as radio-ligand. GRP receptors were detected, often in high density, in 30 of 30 invasive prostatic carcinomas and also in 26 of 26 cases of prostatic intraepithelial proliferative lesions, corresponding mostly to prostatic intraepithelial neoplasias. Well-differentiated carcinomas had a higher receptor density than poorly differentiated ones. Bone metastases of androgen-independent prostate cancers were GRP receptor-positive in 4 of 7 cases. Conversely, GRP receptors were identified in only a few hyperplastic prostates and were localized in very low density in glandular tissue and, focally, in some stromal tissue. In all of the cases, the receptors corresponded to the GRP receptor subtype of bombesin receptors, having high affinity for GRP and bombesin and lower affinity for neuromedin B. These data demonstrate a massive GRP receptor overexpression in prostate tissues that are neoplastically transformed or, like prostatic intraepithelial neoplasias, are in the process of malignant transformation. GRP receptors may be markers for early molecular events in prostate carcinogenesis and useful in differentiating prostate hyperplasia from prostate neoplasia Such data may not only be of biological significance but may also provide a molecular basis for potential clinical applications such as GRP-receptor scintigraphy for early tumor diagnosis, radiotherapy with radiolabeled bombesin-like peptide analogues, and chemotherapy with cytotoxic bombesin analogues.  (+info)

Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. (5/5419)

PURPOSE: To evaluate the prognostic significance of a bone scan index (BSI) based on the weighted proportion of tumor involvement in individual bones, in relation to other factors and to survival in patients with androgen-independent prostate cancer. PATIENTS AND METHODS: Baseline radionuclide bone scans were reviewed in 191 assessable patients with androgen-independent disease who were enrolled onto an open, randomized trial of liarozole versus prednisone. The extent of skeletal involvement was assessed by scoring each scan using the BSI and independently according to the number of metastatic lesions. The relationship of the scored bone involvement to other known prognostic factors was explored in single- and multiple-variable analyses. RESULTS: In single-variable analyses, the pretreatment factors found to be associated with survival were age (P = .0446), performance status (P = .0005), baseline prostate-specific antigen (P = .0001), hemoglobin (P = .0001), alkaline phosphatase (P = .0002), AST (P = .0021), lactate dehydrogenase (P = .0001), and treatment (P = .0098). The extent of osseous disease was significant using both the BSI (P = .0001) and the number of lesions present (P = .0001). In multiple-variable proportional hazards analyses, only BSI, age, hemoglobin, lactate dehydrogenase, and treatment arm were associated with survival. When the patient population was divided into three equal groups, with BSI values of < 1.4%, 1.4% to 5.1%, and > 5.1%, median survivals of 18.3, 15.5, and 8.1 months, respectively, were observed (P = .0079). CONCLUSION: The BSI quantifies the extent of skeletal involvement by tumor. It allows the identification of patients with distinct prognoses for stratification in clinical trials. Further study is needed to assess the utility of serial BSI determinations in monitoring treatment effects. The BSI may be particularly useful in the evaluation of agents for which prostate-specific antigen changes do not reflect clinical outcomes accurately.  (+info)

Biochemical markers of bone turnover in breast cancer patients with bone metastases: a preliminary report. (6/5419)

BACKGROUND: Some biochemical markers of bone turnover are expected to reflect the disease activity of metastatic bone tumor. In the present study six biochemical markers were evaluated to determine appropriate markers for the detection of metastatic bone tumors from breast cancer (BC). METHODS: A panel of bone turnover markers was assessed in 11 normocalcemic patients with bone metastases from BC and in 19 BC patients without clinical evidence of bone metastases. Bone formation was investigated by measuring serum bone isoenzyme of alkaline phosphatase (BALP), osteocalcin (OC) and carboxy-terminal propeptide of type I procollagen (PICP): Bone resorption was investigated by measuring serum carboxy-terminal telopeptide of type I collagen (ICTP), fasting urinary pyridinoline (Pyr) and deoxypyridinoline (D-Pyr). RESULTS: PICP was influenced by age and menopausal status. Significant correlations were observed between each of bone turnover markers except between BALP and OC. The mean levels of the six bone turnover markers were higher in patients with bone metastases than in those without them and significance was observed except for OC. The best diagnostic efficiency by receiver-operating characteristic (ROC) analysis was provided by ICTP followed by Pyr or D-Pyr, BALP, PICP and OC and significance was observed between ICTP and OC. Multiple logistic regression analysis adjusted by age revealed that the only significant marker related to bone metastases was ICTP. CONCLUSIONS: Serum ICTP appears to be the leading marker of bone metastases from BC. However, to reveal the clinical usefulness of these markers, further examination will be needed to account for the ease and cost-effectiveness of the measurements.  (+info)

Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. (7/5419)

BACKGROUND: To apply our preclinical findings of cytotoxic synergy with the combination of estramustine phosphate (EP) and docetaxel as the basis of treatment of hormone refractory metastatic prostate cancer in man. To determine the optimal dosage and the toxicities of these two agents for future trials. PATIENTS AND METHODS: Seventeen patients with hormone refractory metastatic prostate cancer who were ambulatory with performance status < or = 2, normal marrow, renal and hepatic function were entered. Prior exposure to EP or a taxane were exclusion factors. EP was given orally at a dose of 14 mg/kg of body weight daily with concurrent docetaxel administered every 21 days as an intravenous infusion over 1 hour with dexamethasone 8 mg. PO BID for five days. EP dosages were kept static; docetaxel dosages were explored in a minimum of three patients per level for dosages of 40, 60, 70, and 80 mg/m2. Patients were evaluated weekly. Prostate specific antigen (PSA) was measured every three weeks. RESULTS: Five patients were entered at a docetaxel dose of 40 mg/m2, three at 60 mg/m2, six at 70 mg/m2, and three at 80 mg/m2. Only one patient had received prior chemotherapy. Grades 1 or 2 hypocalcemia and hypophosphatemia were seen at all dosage levels. Other grade 2 or less toxicities not related to dosage included alopecia, anorexia, stomatitis, diarrhea, and epigastric pain. Dose limiting toxicities (DLT) as grade 4 leukopenia and grade 4 fatigue were seen at 80 mg/m2. The phase II dose was defined at 70 mg/m2 with rapidly reversible leukopenia and minor liver function abnormalities. At this dosing level, dose intensity was 88% and 86% over consecutive cycles for docetaxel and EP, respectively. Two vascular events occurred at this dose level (70 mg/m2): one arterial and the other venous. PSA decreases greater than 50% from baseline were seen in 14 of 17 patients at all dosage levels. Four of the 17 patients demonstrated a complete biochemical response (PSA < or = 4 ng/ml). One patient had a partial response with measurable lung and liver lesions. CONCLUSION: EP given continuously with every three-week docetaxel at a dose of 70 mg/m2 is tolerable with evidence of antitumor activity based upon significant declines in PSA in the majority of patients and improvement of lung metastasis in one patient. Larger phase II studies of this combination in a homogenous population are warranted.  (+info)

Treatment of localized primary non-Hodgkin's lymphoma of bone in children: a Pediatric Oncology Group study. (8/5419)

PURPOSE: The treatment of primary lymphoma of bone (PLB) in children has traditionally included radiotherapy to the primary site; more recently, it has included systemic chemotherapy. Because of concern about the untoward effects of treatment in a disease that is curable, we attempted to determine whether radiotherapy can be safely excluded from treatment. PATIENTS AND METHODS: The results of three consecutive Pediatric Oncology Group (POG) studies were examined to determine the impact on outcome of radiotherapy as adjunctive treatment in children and adolescents receiving chemotherapy for early-stage primary lymphoma of bone. RESULTS: From 1983 to 1997, 31 patients with localized PLB were entered onto POG studies of early-stage non-Hodgkin's lymphoma (NHL). Between 1983 and 1986, seven patients were treated with 8 months of chemotherapy with irradiation (XRT) of the primary site. After 1986, patients were treated without XRT; four received 8 months of chemotherapy, and 20 received 9 weeks of chemotherapy. Primary sites were the femur (nine), tibia (eight), mandible (five), mastoid (one), maxilla (one), zygomatic arch (one), rib (one), clavicle (one), scapula (one), ulna (one), talus (one), and calcaneous (one). Histologic classification revealed 21 cases of large cell lymphoma, five cases of lymphoblastic lymphoma, two cases of small, noncleaved-cell lymphoma, and three cases of NHL that could not be classified further. One patient relapsed at a distant site 22 months after completion of therapy. There have been no deaths. CONCLUSION: Localized PLB is curable in most children and adolescents with a 9-week chemotherapy regimen of modest intensity, and radiotherapy is an unnecessary adjunct.  (+info)

molecular oncology, university of Chicago, bone tumor, bone cancer, osteosarcoma, soft tissue sarcoma, bone biology, wnt signal, bmp signal, musculoskeletal biology, cancer biology, mesenchymal stem cell differentiation, osteoblast, osteogenesis, osteoblast differentiation, chondrogenesis, chondrocyte, tendon, b-catenin, tong-chuan he, rex c haydon, bone regeneration, fracture healing, articular cartilage regeneration, id LHL protein, CTGF, ccn1, ccn proteins, cyr61, BMP Wnt beta-catenin osteosarcoma bone cancer bone cancer bone tumor bone tumor BMP Wnt beta-catenin osteosarcoma bone cancer bone cancer bone tumor bone tumor BMP Wnt beta-catenin osteosarcoma bone cancer bone cancer bone tumor bone tumor BMP Wnt beta-catenin osteosarcoma bone cancer bone cancer bone tumor bone tumor BMP Wnt beta-catenin osteosarcoma bone cancer bone cancer bone tumor bone tumor BMP Wnt beta-catenin osteosarcoma bone cancer bone cancer bone tumor bone tumor molecular oncology, university of Chicago, bone tumor, ...
molecular oncology, university of Chicago, bone tumor, bone cancer, osteosarcoma, soft tissue sarcoma, bone biology, wnt signal, bmp signal, musculoskeletal biology, cancer biology, mesenchymal stem cell differentiation, osteoblast, osteogenesis, osteoblast differentiation, chondrogenesis, chondrocyte, tendon, b-catenin, tong-chuan he, rex c haydon, bone regeneration, fracture healing, articular cartilage regeneration, id LHL protein, CTGF, ccn1, ccn proteins, cyr61, BMP Wnt beta-catenin osteosarcoma bone cancer bone cancer bone tumor bone tumor BMP Wnt beta-catenin osteosarcoma bone cancer bone cancer bone tumor bone tumor BMP Wnt beta-catenin osteosarcoma bone cancer bone cancer bone tumor bone tumor BMP Wnt beta-catenin osteosarcoma bone cancer bone cancer bone tumor bone tumor BMP Wnt beta-catenin osteosarcoma bone cancer bone cancer bone tumor bone tumor BMP Wnt beta-catenin osteosarcoma bone cancer bone cancer bone tumor bone tumor molecular oncology, university of Chicago, bone tumor, ...
molecular oncology, university of Chicago, bone tumor, bone cancer, osteosarcoma, soft tissue sarcoma, bone biology, wnt signal, bmp signal, musculoskeletal biology, cancer biology, mesenchymal stem cell differentiation, osteoblast, osteogenesis, osteoblast differentiation, chondrogenesis, chondrocyte, tendon, b-catenin, tong-chuan he, rex c haydon, bone regeneration, fracture healing, articular cartilage regeneration, id LHL protein, CTGF, ccn1, ccn proteins, cyr61, BMP Wnt beta-catenin osteosarcoma bone cancer bone cancer bone tumor bone tumor BMP Wnt beta-catenin osteosarcoma bone cancer bone cancer bone tumor bone tumor BMP Wnt beta-catenin osteosarcoma bone cancer bone cancer bone tumor bone tumor BMP Wnt beta-catenin osteosarcoma bone cancer bone cancer bone tumor bone tumor BMP Wnt beta-catenin osteosarcoma bone cancer bone cancer bone tumor bone tumor BMP Wnt beta-catenin osteosarcoma bone cancer bone cancer bone tumor bone tumor molecular oncology, university of Chicago, bone tumor, ...
molecular oncology, university of Chicago, bone tumor, bone cancer, osteosarcoma, soft tissue sarcoma, bone biology, wnt signal, bmp signal, musculoskeletal biology, cancer biology, mesenchymal stem cell differentiation, osteoblast, osteogenesis, osteoblast differentiation, chondrogenesis, chondrocyte, tendon, b-catenin, tong-chuan he, rex c haydon, bone regeneration, fracture healing, articular cartilage regeneration, id LHL protein, CTGF, ccn1, ccn proteins, cyr61, BMP Wnt beta-catenin osteosarcoma bone cancer bone cancer bone tumor bone tumor BMP Wnt beta-catenin osteosarcoma bone cancer bone cancer bone tumor bone tumor BMP Wnt beta-catenin osteosarcoma bone cancer bone cancer bone tumor bone tumor BMP Wnt beta-catenin osteosarcoma bone cancer bone cancer bone tumor bone tumor BMP Wnt beta-catenin osteosarcoma bone cancer bone cancer bone tumor bone tumor BMP Wnt beta-catenin osteosarcoma bone cancer bone cancer bone tumor bone tumor molecular oncology, university of Chicago, bone tumor, ...
From the large reduction in tumor burden brought about by doxycycline, it appears more likely that the effectiveness relies on the properties of doxycycline as an inhibitor of tumor cell proliferation and less on its effect as a MMP inhibitor, because only a relative modest decrease in bone resorption was observed. Other osteolytic bone metastasis models, such as the one using orthotopic injections of 4T1 mouse mammary tumor cells (20) , will be examined in future studies to confirm our data obtained with the MDA-MB-231 cells. Our results suggest that doxycycline may be useful not only for the treatment of osteolytic but also for the treatment of osteoblastic bone metastasis. However, this remains to be determined using animal models specific for osteoblastic bone metastasis, such as the MCF-7 human breast cancer cell model (20) . The mechanism of action of doxycycline is very different from that of the bisphosphonate family of drugs that are used as therapeutic agents in clinical disorders ...
Q: My friend is only 16 but he was just diagnosed with cancer in his leg bone. Is this common?A: There are many cancers that can metastasize to the bones (so these are not primary bone cancers), but there are also some primary bone cancers that arise directly from cancerous bone cells. Osteosarcoma (OS) is the most common primary bone cancer, although overall it is a rare cancer representing only about 1 percent of all cancers diagnosed in the U.S. There are few than 1,000 new cases of OS
Q: My friend is only 16 but he was just diagnosed with cancer in his leg bone. Is this common?A: There are many cancers that can metastasize to the bones (so these are not primary bone cancers), but there are also some primary bone cancers that arise directly from cancerous bone cells. Osteosarcoma (OS) is the most common primary bone cancer, although overall it is a rare cancer representing only about 1 percent of all cancers diagnosed in the U.S. There are few than 1,000 new cases of OS
molecular oncology, university of Chicago, bone tumor, bone cancer, osteosarcoma, soft tissue sarcoma, bone biology, wnt signal, bmp signal, musculoskeletal biology, cancer biology, mesenchymal stem cell differentiation, osteoblast, osteogenesis, osteoblast differentiation, chondrogenesis, chondrocyte, tendon, b-catenin, tong-chuan he, rex c haydon, bone regeneration, fracture healing, articular cartilage regeneration, id LHL protein, CTGF, ccn1, ccn proteins, cyr61, BMP Wnt beta-catenin osteosarcoma bone cancer bone cancer bone tumor bone tumor BMP Wnt beta-catenin osteosarcoma bone cancer bone cancer bone tumor bone tumor BMP Wnt beta-catenin osteosarcoma bone cancer bone cancer bone tumor bone tumor BMP Wnt beta-catenin osteosarcoma bone cancer bone cancer bone tumor bone tumor BMP Wnt beta-catenin osteosarcoma bone cancer bone cancer bone tumor bone tumor BMP Wnt beta-catenin osteosarcoma bone cancer bone cancer bone tumor bone tumor molecular oncology, university of Chicago, bone tumor, ...
molecular oncology, university of Chicago, bone tumor, bone cancer, osteosarcoma, soft tissue sarcoma, bone biology, wnt signal, bmp signal, musculoskeletal biology, cancer biology, mesenchymal stem cell differentiation, osteoblast, osteogenesis, osteoblast differentiation, chondrogenesis, chondrocyte, tendon, b-catenin, tong-chuan he, rex c haydon, bone regeneration, fracture healing, articular cartilage regeneration, id LHL protein, CTGF, ccn1, ccn proteins, cyr61, BMP Wnt beta-catenin osteosarcoma bone cancer bone cancer bone tumor bone tumor BMP Wnt beta-catenin osteosarcoma bone cancer bone cancer bone tumor bone tumor BMP Wnt beta-catenin osteosarcoma bone cancer bone cancer bone tumor bone tumor BMP Wnt beta-catenin osteosarcoma bone cancer bone cancer bone tumor bone tumor BMP Wnt beta-catenin osteosarcoma bone cancer bone cancer bone tumor bone tumor BMP Wnt beta-catenin osteosarcoma bone cancer bone cancer bone tumor bone tumor molecular oncology, university of Chicago, bone tumor, ...
Symptoms of Primary Bone Cancer - Pain, fractures and harmful nervous sensations such as numbness are some of the symptoms of a primary bone cancer. Some other primary bone cancer symptoms includes fatigue, loss of appetite, night sweats, weight loss
Research Report on EMEA (Europe, Middle East and Africa) Metastatic Bone Tumor Treatment Market Report 2017. The Report includes market price, demand, trends, size, Share, Growth, Forecast, Analysis & Overview.
Bibliografía. 1. The Non-Hodgkin´s Lymphoma Pathologic Classifications Project. National Cancer Institute sponsored study of classifications of non-Hodgkins lymphomas: summary and description of a working formulation for clinical usage. Cancer. 1982;49:2112-35. [ Links ] 2. Hogendoorn PCW, Kluin PM. Primary non-Hodgkin lymphoma of bone. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. (eds). WHO Classification of Tumours of Soft Tissue and Bone. 4th ed. Lyon: International Agency for Research on Cancer; 2013. p.316. [ Links ] 3. Jawad MU, Schneiderbauer MM, Min ES, Cheung MC, Koniaris LG, Scully SP. Primary lymphoma of bone in adult patients. Cancer. 2010;116:871-9. [ Links ] 4. Pettit Ck, Zukerberg LR, Gray MH, Ferry JA, Rosenberg AE, Harmon DC, et al. Primary Iymphoma of bone: a B-cell neoplasm with a high frequency of multilobulated cells. Am J Surg Pathol. 1990;14:329-34. [ Links ] 5. Maruyama D, Watanabe T, Beppu Y, Kobayashi Y, Kim SW, Tanimoto K, et al. Primary bone lymphoma: a ...
Recent studies have contributed to the enhancement of clinical and molecular knowledge on bone lymphomas, a group of rare malignancies with particular characteristics. Nevertheless, several questions remain unanswered and the level of evidence supporting some diagnostic and therapeutic decisions remains low. Currently, three different forms of bone lymphomas can be distinguished: the primary bone lymphoma, consisting of a single bone lesion with or without regional lymphadenopathies; the polyostotic lymphoma, consisting of multifocal disease exclusively involving the skeleton; and the disseminated lymphoma with secondary infiltration of the skeleton. The first two forms exhibit a good prognosis, requiring treatments similar to those commonly used for nodal lymphomas of the same category, but several issues regarding the role of surgery and local control of the disease, the sequence of treatment, radiation volumes and doses, management of pathological fractures and prevention of late sequelae deserve
Primary bone lymphoma (PBL) is a rare but distinct clinicopathological disease. Because it is not common, the optimal treatment strategy has not been established. Here, we present a patient with PBL of the left radius and review the related literature. We focus on the standard treatment for PBL. Many aspects such as rehabilitation, local control and overall survival need to be considered. Studies on this disease should be carried out to clarify the optimal treatment in the future.
Tumor-induced bone disease is common among patients with advanced solid cancers, especially those with breast, prostate, and lung malignancies. The tendency of these cancers to metastasize to bone and induce bone destruction is, in part, due to alterations in integrin expression and signaling. Substantial evidence from preclinical studies shows that increased expression of integrin αvβ3 in tumor cells promotes the metastatic and bone-invasive phenotype. Integrin αvβ3 mediates cell adhesion to several extracellular matrix proteins in the bone microenvironment which is necessary for tumor cell colonization as well as the transmission of mechanical signals for tumor progression. This review will discuss the αvβ3 integrin receptor in the context of tumor-induced bone disease. Specifically, the focus will be the role of αvβ3 in modulating cancer metastasis to bone and tumor cell response to the bone microenvironment, including downstream signaling pathways that contribute to tumor-induced osteolysis.
In this case-based interview, oncologist Dan George, MD, discusses the management of a patient who develops prostate cancer bone metastases. Radiologist Rajan Gupta, MD, and radiation oncologist Glen Gejerman, MD, share viewpoints on the use of imaging and bone-targeted therapy for this patient.
TY - JOUR. T1 - Clinical usefulness of bisphosphonates in oncology. T2 - Treatment of bone metastases, antitumoral activity and effect on bone resorption markers. AU - Verì, A.. AU - DAndrea, M. R.. AU - Bonginelli, P.. AU - Gasparini, Giampietro. PY - 2007/1. Y1 - 2007/1. N2 - The present article overviews the role of bisphosphonates for the treatment and prevention of bone metastases and their antiangiogenic effects and antitumoral activity. The skeleton is a frequent and clinically relevant site of metastasis in cancer patients. The major events related to bone metastases include bone pain, bone loss, hypercalcemia, spinal cord compression, and fractures. On the basis of their radiographic features, bone metastases are classified as osteoblastic, osteoclastic, or mixed. The primary goals of treatment of bone metastases are reduction of the risk of pathological fractures and other skeletal-related events, and pain control. Bisphosphonates are used to prevent pathological fractures by ...
Bone metastasis is a complex process that needs to be better understood in order to help clinicians prevent and treat it. Xenografts using patient-derived material (PDX) rather than cancer cell lines are a novel approach that guarantees more clinically realistic results. A primary culture of bone metastasis derived from a 67-year-old patient with breast cancer was cultured and then injected into zebrafish (ZF) embryos to study its metastatic potential. In vivo behavior and results of gene expression analyses of the primary culture were compared with those of cancer cell lines with different metastatic potential (MCF7 and MDA-MB-231). The MCF7 cell line, which has the same hormonal receptor status as the bone metastasis primary culture, did not survive in the in vivo model. Conversely, MDA-MB-231 disseminated and colonized different parts of the ZF, including caudal hematopoietic tissues (CHT), revealing a migratory phenotype. Primary culture cells disseminated and in later stages extravasated from the
Project summary Breast cancer frequently metastasizes to be where it leads to osteolysis and poor clinical prognosis; however, the role of hydroxyapatite nanocrystals (HA, the mineral component of bone) in this process remains unclear due, in part, to the lack of appropriate culture models. The overall goal of these studies is to design a mineralized 3-D tumor model that captures the intrinsic 3-D cell-microenvironment interactions within bone- metastatic niches and nanostructural alterations of HA that may occur due to disease and aging. Specifically, we will develop porous poly (lactide-co-glycolide) (PLG) scaffolds that incorporate HA nanoparticles of defined physicochemical characteristics and assess the applicability and relevance of this 3-D tumor model to test the functional relationships between HA and osteolytic bone metastasis. This work will be accomplished in three specific aims: In Aim 1, we will develop the 3-D matrices by synthesizing monodispersed nanoparticles of HA with ...
Project summary Breast cancer frequently metastasizes to be where it leads to osteolysis and poor clinical prognosis; however, the role of hydroxyapatite nanocrystals (HA, the mineral component of bone) in this process remains unclear due, in part, to the lack of appropriate culture models. The overall goal of these studies is to design a mineralized 3-D tumor model that captures the intrinsic 3-D cell-microenvironment interactions within bone- metastatic niches and nanostructural alterations of HA that may occur due to disease and aging. Specifically, we will develop porous poly (lactide-co-glycolide) (PLG) scaffolds that incorporate HA nanoparticles of defined physicochemical characteristics and assess the applicability and relevance of this 3-D tumor model to test the functional relationships between HA and osteolytic bone metastasis. This work will be accomplished in three specific aims: In Aim 1, we will develop the 3-D matrices by synthesizing monodispersed nanoparticles of HA with ...
The bone marrow provides a specialized and highly supportive microenvironment for tumor growth and development of the associated bone disease. It is a preferred site for breast and prostate cancer bone metastasis and the hematologic malignancy, multiple myeloma. For many years, researchers have focused upon the interactions between tumor cells and the cells directly responsible for bone remodeling, namely osteoclasts and osteoblasts. However, there is ever-increasing evidence for a multitude of ways in which the bone marrow microenvironment can promote disease pathogenesis, including via cancer-associated fibroblasts, the hematopoietic stem cell niche, myeloid-derived suppressor cells, and the sympathetic nervous system. This review discusses the recent advances in our understanding of the contribution of the host microenvironment to the development of cancer-induced bone disease.
Primary bone cancer starts in bone or cartilage while metastatic bone cancers begin elsewhere in the body and spread to bones. Learn about how they differ.
Bone metastases are frequently one of the first signs of disseminated disease in cancer patients. Skeletal complications due to metastatic disease include (severe) bone pain, impaired mobility, spinal cord compression, pathological fractures, and hypercalcemia. Radiotherapy and surgery are the options for the specific local treatment of bone metastases. Chemotherapy, hormonotherapy and bisphosphonates are systemic weapons used in the treatment of bone metastases with or without hypercalcemia. Cancers with propensity to metastasize to bones such as breast, prostate, lung and myeloma may possess the capacity to interact with osteoclasts. Osteoclasts are specialized bone cells, which erode mineralized bone by secreting acids and lysosomal enzymes. In normal bone remodeling, osteoclastic bone resorption is coupled to and is in equilibrium with osteoblastic bone formation. The lytic bone destruction associated with malignant bone metastases develops because tumor cells synthesize and release soluble ...
Recurring breast cancer can sometimes spread to your bones. A long-term study conducted by the by the Hacettepe University Institute of Oncology in Turkey on 141 women with breast cancer and bone metastasis found that the median survival rate was two years, according to ascopubs.org.
EN] Bone metastases are a common complication in some high incidence types of cancer, like prostate or breast cancer. The complications associated with bone metastases include bone pain, fractures and spinal cord compression. Most part of bone metastases are irreversible and treatments are focused on slowing the growth of the lesions. In the United States, 17% of the total direct medical cost was employed treating bone metastases. In order to improve the health of the patients and cut down medical costs, early detection is crucial. Some studies have shown that Whole-Body MRI has the potential to become the best method for diagnosis but there are still some difficulties left. One patient can have multiple bone metastases all over the skeleton in different sizes. This makes diagnosing bone metastases a tough task for the radiologists and because of the irregular shapes of the bone metastases, changes in size are also difficult to measure. The goal of this project is to provide an automatic tool ...
Ablative treatment of metastatic bone tumors and relief of pain associated with metastatic bone tumors is achieved by heat ablation of the bone tumor or tissue near the bone tumor by an ablation probe. In one form the probe is an electrode coupled to a high frequency power supply to provide ablative heating of tissue proximate to an electrode that is placed in or near the bone tumor. Cooling of the electrode by fluid circulation from a cooling apparatus outside the patients body may be used to enlarge the region of high frequency heating around the electrode. Image guidance of the electrode placement may be monitored by an imaging device. Tracking of the electrode by an image-guided navigator helps in placement of the electrode with respect to the configuration of the bone and bone metastasis. A set of tools accommodates biopsy and various shapes of electrodes according to clinical requirements. Several forms of electrodes, energy delivery and cooling apparatus and methods accommodate the specific
R.Coleman explains how the trial results can help plan treatment for women with metastatic BC, highlighting advantages of a less intensified approach
Osteolytic metastases due to breast cancer are serious events. osteoclast activating element. Osteoclasts subsequently resorb launch and bone tissue elements inlayed in the bone tissue matrix, including parathyroid hormone-related peptide (PTHrP), IL-6, and changing growth element (TGF)-, which serve as tumour success factors [1]. Shape 1 Breasts cancer-bone relationships in skeletal metastasis using the receptor activator of NF-B ligand (RANKL)/RANK pathway. Manifestation of RANK allows breast cancers cells to migrate to bone tissue where in fact the cognate ligand RANKL can be abundantly expressed … A significant breakthrough in bone HCL Salt tissue cell biology was Rabbit polyclonal to ERMAP. the recognition of receptor activator of NF-B ligand (RANKL), the stem cell element for osteoclasts [2,3]. RANKL, which is abundantly produced by osteoblasts, stimulates osteoclastic lineage commitment, promotes cellular maturation and functions, and prolongs survival, which together enhance bone ...
Results of the trial were presented today (Sunday) at the 2011 European Multidisciplinary Cancer Congress [1].. Professor Peter Hoskin, consultant clinical oncologist at the Mount Vernon Cancer Centre, Northwood, UK, and Professor of Clinical Oncology at University College, London, and colleagues, randomised 470 patients with primary prostate cancer and painful bone metastases to receive either a single dose of radiation or a single intravenous infusion of the bisphosphonate ibandronate (IB). Patients reported their primary site of pain at entry into the trial, and then at four, eight, twelve, 26 and 52 weeks after treatment.. Those who had not responded to the first treatment at four weeks crossed over to the alternative therapy and received their second treatment no later than week eight. Pain levels were measured at four and twelve weeks by examining analgesic use, using a combination of scoring via the WHO pain ladder [2] and the Mercadante method, which defines analgesic use in morphine ...
This proposal studied the role of TGF Beta signaling in prostate cancer. To summarize, it is a useful target for treatment of prostate cancer bone metastases, provided that the tumor cells are responsive to the factor and show components of osteolytic lesions. TGF Beta inhibitors are not beneficial when the bone metastases phenotype is predominantly osteoblastic. Smad-independent pathways downstream of the TGF Beta receptors, such as p38 MAP kinase, do not appear to be appropriate targets for pharmacological treatment of prostate cancer bone metastases. There is no advantage to combined treatment targeting TGF Beta receptors and p38 MAP kinase. PMEPA1 may be an important target of TGF Beta in prostate cancer cells and responsible for potentiating responsiveness of tumor cells in bone to the local actions of bone-released TGF Beta. Its regulation and isoformspecific effects are complex and will be the subject of future grant proposals. TGF Beta inhibition increases bone mass systemically thru effects to
TY - JOUR. T1 - A csontáttétképzodés molekuláris alapjai és célzott terápiája. AU - Tímár, J.. PY - 2010/3/1. Y1 - 2010/3/1. N2 - Formation of bone metastasis is a hallmark of the progression of several solid cancers, providing example for the organ specificity of the process. Bone metastasis may result in both venous and arterial dissemination. Though the molecular basis of the lytic and plastic bone metastasis formation is different, in reality these organ metastases represent a mixture of the two processes. The basis of bone metastasis formation is the activation of osteoclasts and the resulting bone resorption, initiating a vicious circle by activating the initiator cancer cell. The discovery of osteoclast-bone matrix interaction inhibitor bisphosphonates revolutionized the therapy of bone metastasis. Clarifying the molecular pathways involved in bone metastasis formation identified osteoclast differentiation as another feasible target. This process is under control of the TNF ...
TY - JOUR. T1 - The Characteristics of Bone Metastasis in Patients with Colorectal Cancer. T2 - A Long-Term Report from a Single Institution. AU - Baek, Se Jin. AU - Hur, Hyuk. AU - Min, Byung Soh. AU - Baik, Seung Hyuk. AU - Lee, Kang Young. AU - Kim, Nam Kyu. N1 - Publisher Copyright: © 2015 Société Internationale de Chirurgie.. PY - 2016/4/1. Y1 - 2016/4/1. N2 - Background: Bone metastasis in patients with colorectal cancer (CRC) is very rare, and data are extremely lacking. We aimed to evaluate the characteristics of bone metastasis in patients with CRC. Materials and methods: We performed a chart review of 63 patients (1.1 %) with bone metastasis among 5479 patients who underwent surgery for CRC. Results: Most patients were stage 3 (17.5 %) or 4 (73.0 %), and 32 patients (50.8 %) were diagnosed with bone metastasis at initial diagnoses of CRC. Thirty-one patients developed bone metastasis during the follow-up period with median 10.1-month interval. PET-CT was most frequently used for the ...
While prostate cancer metastatic lesions are the result of dysregulated activities of osteoclasts and osteoblasts, osteoblasts remain the key drivers in prostate cancer progression. Radiological evidence indeed shows osteoblastic lesions found located near osteoblast areas (6) and thus rationalizes an osteoclast-free approach in the first instance, as also highlighted by others (13).. Various models of bone metastasis/metastases have emerged in the past few decades, targeting different aspects of bone metastasis. They include 2D Transwell cocultures, multicellular spheroids (scaffold-free) (26), cell-encapsulated bioprinted/engineered matrices (scaffold-based) (27, 28), and ex vivo cultures (29) and can be used in static or dynamic modes (13). While every model comes with its pros and cons, only a few models have been used to answer relevant biological questions, such as assessing the effects of current or new drugs in the bone tumor microenvironment. An exception is the work by Fong et al. ...
Metastatic Disease Most common malignant lesion of bone. approximately 50 percent of tumors can spread or metastasize to the skeleton. Bone is the third favorite place for metastatic cancers after lung and liver . More than 1.2 million new cases are diagnosed each year Typically multifocal BUT renal and thyroid carcinomas produce only a solitary lesion.
24 yo man with right-sided lower posterior chest/rib pain for 4-6 months, increases with deep inspiration. He denies history of trauma.
Data & statistics on Bone Metastases Therapy: Bone metastases from hormone‐resistant prostate cancer., Kinetic analysis of 18F-fluoride PET images can differentiate osteoblastic and osteolytic lesions in breast cancer metastases. The authors concluded that fluoride flux and transport can be accurately and independently measured for bone metastases and normal vertebrae., Inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer,
Introduction: Bone metastases are the most common cause of cancer-related pain in various primary malignant tumors, most often, breast and prostate. 188Re-hydroxyethylidene diphosphonate (188Re-HEDP) is a new and less expensive bone seeking radiopharmaceutical with favorable physical characteristics of the radionuclide such as short half life of 16.9h, maximal β energy of 2.1 MeV with a 15% γ-component of 155 keV and easily available from an in-house 188W/188Re generator. The aim of this study is to evaluate the therapeutic efficacy and safety profile of bone palliative therapy following administration of 188Re-HEDP. Methods: Twenty patients with painful metastatic bone lesions secondary to breast, prostate, multiple myeloma, ampulla of vater and lung cancers received 1 mCi/kg of 188Re-HEDP. Four hours after treatment, post-therapy scintigraphy was performed. All patients were interviewed using a standard set of questions (visual analogue scale: VAS) concerning their pain relief before, and after
Dottertumörer vid prostatacancer kan spåras via kolesterolDottertumörer i skelettet hos patienter med prostatacancer innehåller höga nivåer av kolesterol och olika aminosyror. Att mäta nivåerna är därför en möjlig väg för att spåra misstänkta dottertumörer. Det visar forskare vid Umeå universitet i en ny studie.Ofta är det förekomsten av dottertumörer, metastaser, som avgör allvaret vid en cancersjukdom. För att behandla patienter med avancerad prostatacancer är det därför viktigt att hitta och identifiera metastaser på ett tidigt stadium. Metastaser från prostatacancer finns ofta i skelettets ben.I studien har forskarna analyserat normal prostatavävnad och vävnad från benmetastaser från patienter med prostatacancer och andra cancersjukdomar. Forskarna har på detta sätt försökt hitta entydiga mönster som utmärker benmetastaser hos patienter med prostatacancer.Något oväntat fann forskarna höga halter av kolesterol i metastasvävnad från patienter med ...
Learn about the causes, symptoms, diagnosis & treatment of Tumors of Bones and Joints from the Professional Version of the Merck Manuals.
DR. K. MSK cases has some excellent information to share with technologists!! make some time to visit this site. Below is an example: Primary lymphoma of the bone accounts for approximately 3% of malignant bone neoplasms and comprises less than 5% of all extranodal non-Hodgkins lymphomas. Diagnosis of primary bone lymphoma includes initial involvement of a single…
This booklet is about primary bone cancer. It covers what it is, the causes, symptoms, how it is diagnosed, treatments and clinical trials.
MeSH-minor] Administration, Oral. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / secondary. Disease Progression. Drug Resistance, Neoplasm. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Niacinamide / analogs & derivatives. Phenylurea Compounds. Prognosis. Remission Induction. Salvage Therapy. Survival ...
Primary malignant bone tumours, osteosarcomas, and Ewing sarcomas are rare diseases which occur mainly in adolescents and young adults. With the current therapies, some patients remain very difficult to treat, such as tumour with poor histological response to preoperative CT (or large initial tumour volume for Ewing sarcomas not operated), patients with multiple metastases at or those who relapsed. In order to develop new therapies against these rare tumours, we need to unveil the key driving factors and molecular abnormalities behind the malignant characteristics and to broaden our understanding of the phenomena sustaining the metastatic phenotype and treatment resistance in these tumours. In this paper, starting with the biology of these tumours, we will discuss potential therapeutic targets aimed at increasing local tumour control, limiting metastatic spread, and finally improving patient survival.
The microenvironment at the site of tumor metastasis plays a key role in determining the fate of the metastasizing tumor cells. This ultimately has a direct impact on the progression of cancer. Bone is the preferred site of metastasis of breast cancer. Painful, debilitating osteolytic lesions are formed as a result of crosstalk between breast cancer cells and cells in the bone, predominantly the osteoblasts and osteoclasts. In this paper, we have discussed the temporal and spatial role of hedgehog (Hh) signaling in influencing the fate of metastatic breast cancer cells in bone. By virtue of its secreted ligands, the Hh pathway is capable of homotypic and heterotypic signaling and consequently altering the microenvironment in the bone. We also have put into perspective the therapeutic implications of using Hh inhibitors to prevent and/or treat bone metastases of breast cancer.
Bone metastasis, or the development of secondary tumors within the bone of cancer patients, is a debilitating and incurable disease. Despite its morbidity, the biology of bone metastasis represents one of the most complex and intriguing of all oncogenic processes. This complexity derives from the intricately organized bone microenvironment in which the various stages of hematopoiesis, osteogenesis, and osteolysis are jointly regulated but spatially restricted. Disseminated tumor cells (DTCs) from various common malignancies such as breast, prostate, lung, and kidney cancers or myeloma are uniquely primed to subvert these endogenous bone stromal elements to grow into pathological osteolytic or osteoblastic lesions ...
TY - JOUR. T1 - Bone cancer. T2 - Clinical practice guidelines. AU - Biermann, J. Sybil. AU - Baker, Laurence H.. AU - Benjamin, Robert. AU - Brigman, Brian. AU - Chow, Warren. AU - Conrad, Ernest U.. AU - Frassica, Deborah. AU - Frassica, Frank J.. AU - George, Suzanne. AU - Healey, John H.. AU - Heck, Robert. AU - Letson, G. Douglas. AU - Mayerson, Joel. AU - Neff, James. AU - ODonnell, Richard J.. AU - Randall, R. AU - Santana, Victor. AU - Satcher, Robert L.. AU - Schmidt, Richard G.. AU - Siegel, Herrick J.. AU - Wong, Michael K.. AU - Yasko, Alan W.. PY - 2005/3/1. Y1 - 2005/3/1. N2 - Primary bone cancers are extremely uncommon, comprise many different types with wide clinical heterogeneity, and are often curable when treated properly. There are many different kinds of primary bone cancers, and the names are principally based on histologic origin. For certain sarcomas, the cell type of origin has not yet been specifically determined. The three most common primary bone sarcomas are ...
Figure 4. TNFR1 expression inversely correlates with survival over the full range of the survival curve over all 143 samples including all primary tumor groups. In all 4 graphs, survival is defined as the number of months each patient survived following the first diagnosis of bone metastasis. A, the total set of 143 samples with known survival data was subdivided into 4 quartiles based on survival time. The mean and median TNFR1 expression in the 4 quartiles descends over the shortest to the longest survivors. The Mann-Whitney test was applied to medians of the lowest (x ≤ 5) and highest (x ≥ 38) survival quartiles. The Kruskal-Wallis test was conducted on the medians of 4 groups of samples. B, this graph depicts the Kaplan-Meier survival curves in the total set of 143 samples, using the median of TNFR1 expressions as the cut point to create the high expressing (high) and the low expressing (low) patients groups. C, Kaplan-Meier survival curves for the 25th and 75th quartile of TNFR1 ...
An achy bone. Constipation. Severe thirst. While these symptoms might not seem to have anything in common, they can all signify more serious conditions, including Metastatic Bone Disease (MBD). Many cancers that start in one place can spread (metastasize) to other areas of the body. When it spreads to the bone, its called MBD.MBD occurs…
BackgroundOsteosarcoma is the most common pediatric malignant bone tumor, frequently surgically managed with limb salvage rather than amputation. Local recurrences are seen in up to 9% of osteosarcoma patients, with CT and MRI imaging often limited by metal artifacts.ObjectiveTo describe the [F-18]2-fluoro-2-deoxyglucose (FDG) PET/CT appearance of local osteosarcoma recurrences with correlation to findings on other imaging modalities.Materials and methodsA retrospective review of pediatric osteosarcoma patients imaged with FDG PET/CT was performed in patients with pathologically proven local recurrences. FDG PET/CT findings were reviewed and correlated with available comparison imaging studies.ResultsTen local osteosarcoma recurrences in eight pediatric osteosarcoma patients were imaged with FDG PET/CT. All eight patients had a local recurrence after limb salvage; two patients had a second local recurrence after amputation. All local recurrences were seen with FDG PET/CT, demonstrating solid (n=5) or
Osteosarcoma is a malignant bone tumor with a high potential for lung metastasis, and the prognosis for patients with metastatic disease is very poor. The interaction between fibronectin (FN) and integrin αvβ3 in soft-tissue sarcoma promotes cell migration, invasion, and lung metastasis. This study aimed to investigate the prognostic significance of FN and αvβ3 in osteosarcoma. Immunohistochemistry and western blotting were used to detect the expression of FN and αvβ3 in 60 osteosarcoma specimens and in 30 osteochondroma specimens. Furthermore, correlations of FN and αvβ3 with the clinicopathological features of osteosarcoma patients were analyzed using the χ2 test and Fishers exact test. Disease-free survival and overall survival of osteosarcoma patients were assessed using the Kaplan-Meier method and Cox proportional hazards model. The predictive accuracy of the model was determined by the Harrell concordance index. FN (P | 0.05) and αvβ3 (P | 0.05) were overexpressed in osteosarcoma
We will conduct a prospective trial to verify the validity of indices utilizing TGF-b1, NF-kB, PET/CT, and MRS for predicting response to neoadjuvant chemotherapy in osteosarcoma patients. We assume that changes in plasma TGF-b1 levels, PET/CT and magnetic resonance spectroscopy (MRS) findings during the period of neoadjuvant chemotherapy as well as the initial nuclear NF-kB expression status of tumor biopsy specimen either alone or in combination may predict a chemotherapeutic response determined by histopathologic necrosis fractions of tumors removed. To test this, we will obtain TGF-b1 levels, PET/CT and MRS findings at diagnosis and at follow-up (after first and second/third chemotherapy cycle). Tumor will then be removed. Chemotherapy regimen comprised of various combination of cisplatin, adriamycin, and high-dose methotrexate, ifosfamide, and etoposide. Indices derived from TGF-b1, PET/CT, MRS predicting greater than 90% necrosis fractions will be sought utilizing statistical methods ...
Osteosarcomas are the most common primary malignant bone tumor that occurs in children and adolescents, and they frequently occur around the knee. In the past, amputation or joint disarticulation was the standard of care. Currently, more than 90% of osteosarcoma resections are limb-sparing procedures because of advancements in chemotherapeutic regimens and three-dimensional imaging studies, including CT and MRI. In addition, joint-sparing surgery is possible in select patients. To preserve the joint structure for good limb function in patients with osteosarcoma, we have been performing epiphyseal or metaphyseal osteotomy and biologic reconstruction via frozen autograft treated with liquid nitrogen. Several advantages are expected with the use of the freezing technique. This strategy involves simple surgical technique without specialized devices. A perfect fit is achieved because the managed bone is the patients own and bone strength is maintained postoperatively. Satisfactory bone union and
article: High-grade osteosarcoma of the extremities - Minerva Ortopedica e Traumatologica 2002 December;53(4):195-204 - Minerva Medica - Journals
Title: Bone Seeking Radiopharmaceuticals for Palliation of Pain in Cancer Patients with Osseous Metastases. VOLUME: 7 ISSUE: 4. Author(s): M.G.E.H. Lam, J.M.H. de Klerk, P.P. van Rijk and B.A. Zonnenberg. Affiliation:University Medical Center Utrecht, Department of Nuclear Medicine, P.O. Box 85500, 3508 GA Utrecht, The Netherlands.. Keywords:Bone metastases, Radionuclide therapy, Pain palliation, Samarium-153-EDTMP, Rhenium-186-HEDP, Strontium-89-Chloride. Abstract: Many patients with cancer develop symptomatic skeletal metastases at an advanced stage of their disease. Skeletal metastases are often complicated by pain. They cause considerable morbidity and mortality. Besides analgesics, treatment options include external beam radiotherapy, bisphosphonates, chemotherapy, surgery and bone seeking radiopharmaceuticals. Pain palliation with bone seeking radiopharmaceuticals has proved to be an effective treatment modality in patients with metastatic bone pain. Radiopharmaceuticals bind to the bone ...
TY - JOUR. T1 - Secondary osteosarcoma. T2 - Is there a predilection for the chondroblastic subtype?. AU - Barker, Jordan P.. AU - Monument, Michael J.. AU - Jones, Kevin B.. AU - Putnam, Angelica R.. AU - Randall, R. PY - 2015/5/1. Y1 - 2015/5/1. N2 - Osteosarcoma is the most common form of primary bone cancer in the adolescent and young adult patient population. Outcomes in patients with secondary osteosarcoma are inferior compared with outcomes in patients with primary osteosarcoma. The goal of this study was to investigate whether there is a predilection for the chondroblastic histologic subtype in secondary osteosarcoma. A retrospective chart review was performed to identify cases of secondary osteosarcoma treated at 1 institution from 1991 to 2012. Histologic subtypes were evaluated by a pathologist, and a review of the literature was also performed to identify the histologic subclassification of additional series of secondary osteosarcomas. Of a total of 131 cases of osteosarcoma, 9 ...
Prostate cancer metastases primarily localize in the bone where they induce a unique osteoblastic response. Elevated Notch activity is associated with high-grade disease and metastasis. To address how Notch affects prostate cancer bone lesions, we manipulated Notch expression in mouse tibia xenografts and monitored tumor growth, lesion phenotype, and the bone microenvironment. Prostate cancer cell lines that induce mixed osteoblastic lesions in bone expressed 5-6 times more Notch3, than tumor cells that produce osteolytic lesions. Expression of active Notch3 (NICD3) in osteolytic tumors reduced osteolytic lesion area and enhanced osteoblastogenesis, while loss of Notch3 in osteoblastic tumors enhanced osteolytic lesion area and decreased osteoblastogensis. This was accompanied by a respective decrease and increase in the number of active osteoclasts and osteoblasts at the tumor-bone interface, without any effect on tumor proliferation. Conditioned medium from NICD3-expressing cells enhanced osteoblast
Osteosarcoma, a primary bone cancer. The osteosarcoma is one of the primary cancers of the bone, that is to say developed from bone cells, cartilage or fibrous tissue, as opposed to secondary cancers of the bone metastases that are of cancer in another organ. The osteosarcoma is primary bone cancer the most common, before the chondrosarcoma, Ewings sarcoma and multiple myeloma . Of unknown cause, osteosarcoma usually occurs in children and young adults, between 10 and 25 years. The bones are usually affected long bones near the knee or shoulder: tibia, femur and humerus. We traditionally distinguish two forms of osteosarcoma: one attacks the central part of the bone (medullary bone), the other in the peripheral zone of the bone, destroying the periosteum, the membrane that surrounds the bone and is responsible for its growth in thickness. You should also remember that osteosarcoma can spread through the bloodstream and invade the lungs causing pulmonary metastases.. The first signs of ...
Eight patients presented without any evidence of metastatic disease; 4 of them had advanced local disease, including large tumour mass with soft-tissue compromise, neurovascular encasement and pathological fracture. Limb salvage was performed in 2/8 patients who presented without metastatic disease, both of whom had a proximal tibial tumour, and underwent wide resection and megaprosthesis total knee replacement.. Three of the patients were older than expected for primary osteosarcoma, aged 40, 51 and 53 years, respectively. Two of these patients were HIV-1 infected; further research is being conducted to determine the causality, if any, between osteosarcoma and HIV-1 infection.. Discussion. Osteosarcoma is a primary malignant bone tumour that is characterised by the proliferation of malignant mesenchymal cells capable of the direct production of osteoid.3,4,6,9 The World Health Organizations histological classification further divides osteosarcoma into medullary and surface tumours, which are ...
LAUBSCHER, M; HELD, M e DUNN, RN. Primary bone tumours of the spine: Presentation, surgical treatment and outcome. SA orthop. j. [online]. 2015, vol.14, n.2, pp.22-28. ISSN 2309-8309. http://dx.doi.org/10.17159/2309-8309.. BACKGROUND: Primary bone tumours of the spine are a group of rare tumours that include both benign and malignant lesions. Resection is associated with a high morbidity rate. METHODS: We retrospectively reviewed all the primary bone tumours of the spine that were surgically treated at our unit between 2005 and 2012 (haematological malignancies were excluded. RESULTS: Fifteen cases were included that presented at a median age of 36 years (range 8 to 65 years). Pain was the most common presenting symptom. Three patients had significant neurological deficits at time of presentation and in two cases there was an improvement after surgery. The median delay in diagnosis was 7 months (range 1 to 36 months). A variety of surgical strategies was employed with the use of adjuvant radio- ...
To estimate the costs (paid amounts) of palliative radiation episodes of care (REOCs) to the bone for patients with bone metastases secondary to breast or prostate cancer. Claims-linked medical records from patients at 98 cancer treatment centers in 16 US states were analyzed. Inclusion criteria included a primary neoplasm of breast or prostate cancer with a secondary neoplasm of bone metastases; ≥2 visits to ≥1 radiation center during the study period (1 July 2008 through 31 December 2009) on or after the metastatic cancer diagnosis date; radiation therapy to ≥1 bone site; and ≥1 complete REOC as evidenced by a |30-day gap pre- and post-radiation therapy. The total number of REOCs was 220 for 207 breast cancer patients and 233 for 213 prostate cancer patients. In the main analysis (which excluded records with unpopulated costs) the median number of fractions per a REOC for treatment of metastases was 10. Mean total radiation costs (i.e., radiation direct cost + cost of radiation-related
TY - JOUR. T1 - Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. AU - Lussier, Danielle M.. AU - ONeill, Lauren. AU - Nieves, Lizbeth M.. AU - McAfee, Megan S.. AU - Holechek, Susan A.. AU - Collins, Andrea W.. AU - Dickman, Paul. AU - Jacobsen, Jeffrey. AU - Hingorani, Pooja. AU - Blattman, Joseph. PY - 2015/3/27. Y1 - 2015/3/27. N2 - Osteosarcoma is the most common bone cancer in children and adolescents. Although 70% of patients with localized disease are cured with chemotherapy and surgical resection, patients with metastatic osteosarcoma are typically refractory to treatment. Numerous lines of evidence suggest that cytotoxic T lymphocytes (CTLs) limit the development of metastatic osteosarcoma. We have investigated the role of PD-1, an inhibitory TNFR family protein expressed on CTLs, in limiting the efficacy of immune-mediated control of metastatic osteosarcoma. We show that human metastatic, but not primary, osteosarcoma tumors express a ...
The reciprocal interaction between cancer cells and the tissue-specific stroma is critical for primary and metastatic tumor growth progression. Prostate cancer cells colonize preferentially bone (osteotropism), where they alter the physiological balance between osteoblast-mediated bone formation and osteoclast-mediated bone resorption, and elicit prevalently an osteoblastic response (osteoinduction). The molecular cues provided by osteoblasts for the survival and growth of bone metastatic prostate cancer cells are largely unknown. We exploited the sufficient divergence between human and mouse RNA sequences together with redefinition of highly species-specific gene arrays by computer-aided and experimental exclusion of cross-hybridizing oligonucleotide probes. This strategy allowed the dissection of the stroma (mouse) from the cancer cell (human) transcriptome in bone metastasis xenograft models of human osteoinductive prostate cancer cells (VCaP and C4-2B). As a result, we generated the osteoblastic
Deregulation of microRNA (miRNA) transcript levels has been observed in many types of tumors including osteosarcoma. Molecular pathways regulated by differentially expressed miRNAs may contribute to the heterogeneous tumor behaviors observed in naturally occurring cancers. Thus, tumor-associated miRNA expression may provide informative biomarkers for disease outcome and metastatic potential in osteosarcoma patients. We showed previously that clusters of miRNAs at the 14q32 locus are downregulated in human osteosarcoma. Human and canine osteosarcoma patients samples with clinical follow-up data were used in this study. We used bioinformatics and comparative genomics approaches to identify miRNA based prognostic biomarkers in osteosarcoma. Kaplan-Meier survival curves and Whitney Mann U tests were conducted for validating the statistical significance. Here we show that an inverse correlation exists between aggressive tumor behavior (increased metastatic potential and accelerated time to death) and the
Ewings sarcoma: a primary bone cancer. Ewing sarcoma is one of the primary tumors of bone, that is to say that cancer cells originate from bone, and that are not met static cancer located elsewhere in another organ. Ewing sarcoma is unique in touch more often men than women. It also develops mainly in children between 10 and 15 years , more rarely in young adults up to age 25. Cancer cells usually reach the long bones like the femur and tibia. Thus Ewing sarcoma most often for the arms and legs, even though this cancer can affect any bone.. Bone cancer: what are the symptoms of Ewings sarcoma?. The symptoms are typically those of bone cancer: bone cancer is painful and swollen. Moreover, it is fragile and may break at the slightest shock. When the tumors grew, they can sometimes go up to affect the bone throughout its length. The diagnosis of Ewings sarcoma is based on the radiograph but also require a confirmatory biopsy. It depletes cells in the suspicious area for examination and to ...
Osteolytic bone metastases are frequent in patients with advanced cancer of the breast, lung, and (to a lesser extent) the prostate. Roentgenography, bone scintigraphy, and bone biopsies are commonly used for the early identification and follow-up of these conditions. These methods have though marked shortcomings as they are all static methods giving a picture of the current situation in bone but not telling about rate of changes taking place in bone. Metabolic bone markers have been shown to be a useful tool for monitoring metastatic bone activity.. It has been shown that there are two different pathways of bone resorption: the cathepsin K-mediated pathway, which is active during physiological resorption of bone, and the matrix metalloproteinase pathway, which functions mainly in pathological situations. ICTP specifically reflects matrix metalloproteinase-mediated pathological degradation of bone collagen (1, 2). ICTP is thus a highly specific marker of bone degradation in bone metastasis and ...
BACKGROUND: Cancer-induced bone pain (CIBP) is a severe chronic pain that is less than adequately controlled by conventional analgesics. Prostatic acid phosphatase (PAP) has been considered as a diagnostic marker for prostate cancer and its transmembrane isoform has been reported to play an antinociceptive effect in neuropathic and inflammatory pain. However, it remains unknown whether it has an analgesic effect on CIBP and what are the underlying mechanisms.. OBJECTIVE: In the present study, we tested whether PAP could alleviate the pain symptoms induced by bone cancer in a rat model.. STUDY DESIGN: A randomized, double blind, and controlled rat animal trial.. METHODS: We first established a rat CIBP model and observed the spinal expression of PAP by immunofluorescence histochemistry and Western blot. Then, PAP (0.1, 0.3, or 1 μg) was intrathecally administered in the CIBP rats in a repeated manner from 15 to 18 days (once per day) after inoculation of tumor cells. On postoperative day (POD) ...
TY - JOUR. T1 - Targeting CDKs with roscovitine increases sensitivity to DNA damaging drugs of human osteosarcoma cells. AU - Vella, Serena. AU - Tavanti, Elisa. AU - Hattinger, Claudia. AU - Fanelli, Marilù. AU - Versteeg, Rogier. AU - Koster, Jan. AU - Picci, Piero. AU - Serra, Massimo. PY - 2016/11/1. Y1 - 2016/11/1. N2 - Cyclin-dependent kinase 2 (CDK2) has been reported to be essential for cell proliferation in several human tumours and it has been suggested as an appropriate target to be considered in order to enhance the efficacy of treatment regimens based on the use of DNA damaging drugs. We evaluated the clinical impact of CDK2 overexpression on a series of 21 high-grade osteosarcoma (OS) samples profiled by using cDNA microarrays. We also assessed the in vitro efficacy of the CDKs inhibitor roscovitine in a panel of drug-sensitive and drug-resistant human OS cell lines. OS tumour samples showed an inherent overexpression of CDK2, and high expression levels at diagnosis of this kinase ...
Fibro osseous lesions area diverse group of disorders characterized by replacement of normal archi- tecture of bone by a benign connective tissue matrix that displays various amount ofmineralizationin the form of woven bone or cementum. It includes developmental, reactive and neoplastic lesions. The different type of fibro-osseous lesions express a common clinical and radiological features. Soad- equate knowledge and clinical observationare necessary for proper interpretation and appropriate diagnosis of these lesions.becausemanagement of patients with fibro-osseous lesions are case specificandindividualized.The aim of this study was to analyse the clinical, radiological and histo- pathological characteristics of fibro osseous lesions andprovide a proper management system affect- ed by this type of lesions. Materials and methods:The retrospective study was performed in the Department of Oral & Maxillofacial surgery, Dhaka Dental College and Hospital, Dhaka, Bangladesh from a period of January ...
Osteosarcoma is a rare neoplasm that develops in bone tissue. Our osteosarcoma patients receive efficient, coordinated treatment from a multidisciplinary team of specialists that include pediatric ...
According to Orthobullets, the life expectancy for someone with metastatic bone cancer is about six months. However, WebMD points out that this depends largely on age of the patient and how far along...
MeSH-minor] Aged. Anti-Bacterial Agents / therapeutic use. Arthroplasty, Replacement, Knee / adverse effects. Debridement. Decision Making. Device Removal. Gram-Positive Bacterial Infections / drug therapy. Gram-Positive Bacterial Infections / surgery. Humans. Knee Prosthesis / adverse effects. Male. Mental Competency. Mental Disorders / diagnosis. Mental Disorders / psychology. Neoplasms, Unknown Primary / diagnosis. Prosthesis-Related Infections / drug therapy. Prosthesis-Related Infections / surgery. Recurrence. Suppuration. Treatment ...
Fingerprint Dive into the research topics of Synchronous Bony and Soft Tissue Metastases from Follicular Carcinoma of the Thyroid. Together they form a unique fingerprint. ...
Limb salvage surgery has become the standard treatment for malignant primary bone tumors in the extremities. Limb salvage represents a challenge in skeletally immature patients. Several treatment options are available for limb reconstruction after tumor resection in children. We report our results using the technique of epiphyseal sparing and reconstruction with frozen autograft bone in 18 children. The mean follow-up period for the all patients included in this study is 72 ± 26 m. Eight patients remained disease-free, seven patients lived with no evidence of disease, two were alive but with disease, and one patient died of the disease. Five- and ten-year rates of survival were 94.4%. Graft survival at 5 and 10 years was 94.4%. Functional outcome using the Enneking scale was excellent in 17 patients (94.4%) and poor in one patient (5.5%). Complications include 2 nonunions, 2 fractures, 2 deep infections, 1 soft tissue recurrence, and leg length discrepancy in 7 cases.
AIM Since the introduction of chemotherapy, survival in localised high-grade osteosarcoma has improved considerably. However, there is still no worldwide consensus on a standard chemotherapy approach. In this systematic review evidence for effectiveness of each single drug and the role of response guided salvage treatment of adjuvant chemotherapy are addressed, whereas in a meta-analysis the number of drugs in current protocols is considered. METHODS A systematic literature search for clinical studies in localised high-grade osteosarcoma was undertaken, including both randomised and non-randomised trials. Historical clinical studies from the pre-chemotherapy era were included for comparison purposes. RESULTS Nine historical studies showed a long-term survival of 16% after only local treatment. Fifty single agent phase II studies showed high response rates for adriamycin (A, 43%), ifosfamide (Ifo, 33%), methotrexate (M, 32%), cisplatin (P, 26%) but only 4% for etposide (E). In 19 neo-adjuvant studies
Osteosarcoma (OS) is a high-grade malignant bone tumor. Therefore, using both in vitro and in vivo assays, the effects of degraded iota-Carrageenan (ι-CGN) on a human osteosarcoma cell line, HOS, were examined. Degraded ι-CGN was observed to induce apoptosis and G(1) phase arrest in HOS cells. Moreo …
Osteosarcoma is among the most frequently occurring primary bone tumors, primarily affecting adolescents and young adults. Despite improvements in osteosarcoma treatment, more specific molecular targets are needed as potential therapeutic options. One target of interest is α-Ca2+/calmodulin-dependent protein kinase II (α-CaMKII), a ubiquitous mediator of Ca2+-linked signaling, which has been shown to regulate tumor cell proliferation and differentiation. Here, we investigate the role of α-CaMKII in the growth and tumorigenicity of human osteosarcoma. We show that α-CaMKII is highly expressed in primary osteosarcoma tissue derived from 114 patients, and is expressed in varying levels in different human osteosarcoma (OS) cell lines [MG-63, N-methyl-N′-nitro-N-nitrosoguanidine (MNNG)/HOS, and 143B). To examine whether α-CaMKII regulates osteosarcoma tumorigenic properties, we genetically inhibited α-CaMKII in two osteosarcoma cell lines using two different α-CaMKII shRNAs delivered by ...
Osteosarcoma (OS) is the most common, non-hematopoietic, primary malignant bone tumor. OS is characterized by its aggressive local growth and systemic dissemination. Although combination of surgical operation and adjuvant chemotherapy greatly improved the prognosis, more than 20% of patients still cannot get long-term survival. Therefore, novel therapeutic approaches should be expected to be developed. Previously, we developed an OS mouse model by overexpressing c-MYC in bone marrow stromal cells derived from Ink4a/Arf knockout mice. We isolated highly tumorigenic cells (designated AXT cells) from tumors after serial transplantation. Inoculation of AXT cells into syngeneic C57BL/6 mice results in the development of lethal OS with metastatic lesions including lung, which pathologically and clinically mimics human osteoblastic osteosarcoma. To obtain the novel therapeutic agents for OS, we performed drug screening using existing drug collections and found that statins strongly suppressed AXT cell ...
In this study, we showed that TGF-β signaling in prostatic fibroblasts contributed to subsequent prostate cancer bone metastasis through paracrine interactions. Conditioned medium prepared from koPFs promoted the early development and growth of prostate cancer mixed bone lesions in the tibiae of mice. This effect was, in part, mediated by elevated expression of cytokines CXCL16 and CXCL1 present in the koPFCM, which stimulated prostate cancer cell adhesion to the bone matrix and induced proliferation at an early stage.. It is well established that stromal TGF-β signaling is important for prostate tissue development as well as prostate cancer initiation and progression (9, 26-29). TGF-β is abundant in the bone matrix, and that the release of TGF-β from the matrix is a critical component for the vicious cycle of osteoclastic bone metastasis (12). Inhibition of TGF-β with small-molecule inhibitors or neutralizing antibodies has previously been shown to decrease osteolytic bone lesion ...
TY - JOUR. T1 - CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma. T2 - Analysis within a group of patients, all of whom developed lung metastasis. AU - Oda, Yoshinao. AU - Yamamoto, Hidetaka. AU - Tamiya, Sadafumi. AU - Matsuda, Shuichi. AU - Tanaka, Kazuhiro. AU - Yokoyama, Ryohei. AU - Iwamoto, Yukihide. AU - Tsuneyoshi, Masazumi. PY - 2006/5/1. Y1 - 2006/5/1. N2 - The chemokine, CXCL12, and its receptor, CXCR4, have recently been shown to play an important role in metastasis of several kinds of carcinoma. It has also been demonstrated that VEGF regulates both the expression of CXCR4 and invasiveness in breast cancer cell lines. We compared the immunohistochemical expression of CXCR4 and VEGF between the primary site and a concordant pulmonary metastatic site in 30 osteosarcoma patients, all of which had undergone thoracotomy. Microvessel density (MVD) as shown by immunostaining of CD34 and proliferative activity with MIB-1 monoclonal antibody was ...
18 Apr 2017. When cancer metastases, bone unwittingly offers a friendly place for tumour cell growth--only to have its hospitality betrayed by pathologic fractures, spinal cord compression, the need for bone surgery or irradiation, and an increased risk of death.. In the largest-known study on bone metastases in thyroid cancer, researchers at the University of Michigan Comprehensive Cancer Center found that patients with follicular and medullary thyroid cancer had the highest rate of cancer-related bone lesions and fractures and an increased risk of death.. We know that metastases are bad.. But patients in our study who had bone metastases had a worse survival rate compared to patients who had metastases at other distant sites, says Megan Haymart, M.D., assistant professor of medicine at Michigan Medicine and one of the researchers on the study.. This suggests that bone metastases are a uniquely poor prognostic indicator.. However, patients with localised or regional thyroid cancer---without ...
AICAR induces mitochondrial apoptosis in human osteosarcoma cells through an AMPK-dependent pathwayAICAR induces mitochondrial apoptosis in human osteosarcoma cells through an AMPK-dependent pathway ...
Title:Reversal of Bone Cancer Pain by HSV-1-Mediated Silencing of CNTF in an Afferent Area of the Spinal Cord Associated with AKT-ERK Signal Inhibition. VOLUME: 14 ISSUE: 5. Author(s):Xu Yang, Jia Liu, Zun-Jing Liu, Qing-Jie Xia, Mu He, Ran Liu, Wei Liu, Wei Wang, Jin Liu, Xin-Fu Zhou, Yun-Hui Zhang and Ting-Hua Wang. Affiliation:Department of Anesthesiology and Institute of Neurological Disease, Translation Neuroscience Center, State Key Lab of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, PR China.. Keywords:Bone cancer pain, CNTF, gene therapy, HSV-1, intrathecal catheterization.. Abstract:Pain induced by bone metastases has a strong impact on the quality of life of patients with cancer, but current therapies for bone cancer pain cannot attain a satisfactory therapeutic goal because of various adverse reactions. Currently, advanced monitoring is required to clarify pathogenic mechanisms, so as to develop more effective treatments. We constructed herpes simplex virus ...
Osteogenic sarcoma (also called osteosarcoma) is the most common tumor of bone. Approximately 1,000 cases of osteogenic sarcoma are seen in the United States each year. A second peak of incidence of osteosarcoma occurs in the eighth decade of life, typically associated with Paget bone disease. Osteosarcoma typically affects adolescents and generally occurs in bones around the knee joint, though any bone of the body can be affected. Treatment typically involves chemotherapy and surgery to try to achieve the best cure rate. Standard drugs include doxorubicin and cisplatin in adults and the same two drugs with high-dose methotrexate in children, adolescents, or young adults.. Recurrences typically occur in the lungs. Surgical removal of lung metastases from a primary osteosarcoma is a standard of care when there is a small number of lung nodules that can be removed safely, and can be associated with a 30-35% cure rate. Osteosarcomas occur commonly in familial syndromes associated with sarcoma, such ...
The present study demonstrates that a high level of YY1 protein expression increases the risk of metastasis (4.69-fold) and poor survival (8.35-fold) in osteosarcoma patients independently of covariates such as age, gender, histotype, and chemonecrosis. We report that the highest range of YY1 expression is a statistically significant prognostic factor setting the 5-year survival rate to 34% in patients with osteosarcoma. These results are in line with literature data and with the tumor necrosis rate which is currently the strongest clinical prognostic factor after chemotherapy [2, 23, 24].. Overall, the molecular complexity of osteosarcoma makes the known prognostic markers of limited utility [12, 25]. A multiple panel of biomarkers in addition to clinical parameters would be useful for predicting prognosis [25]. In this setting, YY1 is the first osteosarcoma marker whose overexpression has been correlated with low metastasis-free and poor overall survival in a higher frequency of cases (61% in ...
Alkaline Phosphatase, serum Bone-specific alkaline phosphatase (BAP.) When alkaline phosphatase is measured, it is actually the sum of the bone-specific and liver-specific components (isoenzymes.) BAP can indicate excess osteoblastic cell activity which may indicate bone metastases. Metra Systems, Inc., says that Bone Alkaline Phosphatase is an osteoblast membrane-bound molecule which is involved in bone formation. Levels of this enzyme are thought to be indicative of the activity of osteoblasts. Another description of AlkPhos is that it is an enzyme that is found on the surface of osteoblasts(the cells that build bone) and as such is used as a serum marker of increased osteoblast activity. Since bone is being added at prostate cancer bone metastases, an increased alkaline phosphatase can mean increased bone met formation. A recent paper by MR Smith et al in Urology discussed BAP and NTx in their role as predictors of skeletal complications in HRPC patients (MR Smith, et al, Urology 70: 315-319, ...
Breast cancer is the second leading cause of cancer-related death in women in the United States. During the advanced stages of disease, many breast cancer patients suffer from bone metastasis. These metastases are predominantly osteolytic and develop when tumor cells interact with bone. In vivo models that mimic the breast cancer-specific osteolytic bone microenvironment are limited. Previously, we developed a mouse model of tumor-bone interaction in which three mouse breast cancer cell lines were implanted onto the calvaria. Analysis of tumors from this model revealed that they exhibited strong bone resorption, induction of osteoclasts and intracranial penetration at the tumor bone (TB)-interface. In this study, we identified and used a TB microenvironment-specific gene expression signature from this model to extend our understanding of the metastatic bone microenvironment in human disease and to predict potential therapeutic targets. We identified a TB signature consisting of 934 genes that were
Cryoablation, a form of low-temperature thermal ablation, has a long history in the treatment of primary and metastatic neoplasms of the kidney, liver, lung, and prostate. Cryoablation is a relatively new technique in the palliative treatment of bone metastases, with the first prospective trial reported in 2006 demonstrating its safety and efficacy.. Argon gas flowing through a sealed probe creates an ice ball due to rapid expansion of the pressurized gas in the sealed probe tip, resulting in a temperature drop to -100C within seconds (Joules-Thomson effect). Helium gas is then used to attain active thawing of the ice ball. The size of the ablation depends on the diameter of the cryoprobe, the length of the uninsulated tip, and the time of freezing.. A single freeze-passive thaw-freeze cycle is performed for 10-5-10 minutes, respectively. Unlike that for RF ablation, the ablation zone in cryoablation can be monitored directly with computed tomography (CT) as a low attenuation elliptical region ...
Primary bone cancer starts in bone cells. Learn about symptoms, diagnosis, treatment and risks in our guide to primary bone cancer.
Primary bone cancer starts in bone cells. Learn about symptoms, diagnosis, treatment and risks in our guide to primary bone cancer.
Osteosarcoma is the most common bone tumor that occurs in dogs. Early diagnosis and intervention are key to maximizing a positive outcome.
SPEAKER: Janet Funk, MD; Dr. Funk is a Professor of Medicine, Bio 5 Institute and Nutritional Sciences, at the University of Arizona. Dr. Funk the leader of an NIH-funded research program with a strong focus on metastatic breast cancer that spans the research spectrum from bench to bedside. Current translational projects are focusing on investigating the utility of turmeric dietary supplements as adjuvant therapeutics for the prevention of breast cancer bone metastases. ...
Coley, William (1949). Neoplasms of Bone. New York: Medical Book Department of Harper & Brothers. pp. 565-570. Chang AE, Shu S ... Dashiell visited Coley after suffering from a hand injury which he soon discovered to be an aggressive bone tumor. Treatment ... McCarthy, Edward (2006). "The Toxins of William B. Coley and the Treatment of Bone and Soft-Tissue Sarcomas". The Iowa ... William Bradley Coley (January 12, 1862 - April 16, 1936) was an American bone surgeon and cancer researcher best known for his ...
Oliveira AM, Chou MM (January 2014). "USP6-induced neoplasms: the biologic spectrum of aneurysmal bone cyst and nodular ... Oliveira AM, Chou MM (January 2014). "USP6-induced neoplasms: the biologic spectrum of aneurysmal bone cyst and nodular ... They typically present with a tumor in areas of the head that lay directly over the temporal or parietal bones. Individual ... Hiemcke-Jiwa LS, van Gorp JM, Fisher C, Creytens D, van Diest PJ, Flucke U (December 2020). "USP6-Associated Neoplasms: A ...
Due to thin bone and weak barriers, the neoplasm can extend into the sinonasal passages, pterygomaxillary fossa and eventually ... Smaller mandibular neoplasms have been enucleated where the cavity of the tumour is curetted, allowing preservation of the bone ... Recurrence within a bone graft (following resection of the original tumor) does occur, but is less common. Seeding to the bone ... Preferable removal includes 10mm of normal bone around the neoplasm. Larger ameloblastomas can require partial resection of the ...
Myeloid neoplasms always concern bone marrow cell lineage and are related to hematopoietic cells. Myeloid tissue can also be ... Myeloid tissue, in the bone marrow sense of the word myeloid (myelo- + -oid), is tissue of bone marrow, of bone marrow cell ... Yuan J, Nguyen CK, Liu X, Kanellopoulou C, Muljo SA (2012). "Lin28b reprograms adult bone marrow hematopoietic progenitors to ... lineage, or resembling bone marrow, and myelogenous tissue (myelo- + -genous) is any tissue of, or arising from, bone marrow; ...
Effect of Sr90 Upon Life Span and Neoplasms of Bone and the Blood-forming Tissues. Miriam P. Finkel, Birute O. Biskis, and ... Delayed effects of bone-seeking radionuclides (Ed. Mays, C.W., et al.). 417. Finkel, M. P., Biskis, B. O., & Jinkins, P. B. ( ... Finkel, M. P., Biskis, B. O., & Scribner, G. M. (1958). The influence of strontium-90 upon life span and neoplasms of mice (No ... 1960). Illinois bone tumor death certificate study. Annual report-Division of Biological and Medical Research. Argonne National ...
... is an uncommon osteoid tissue-forming primary neoplasm of the bone. It has clinical and histologic manifestations ... of all primary bone tumors and only 14% of benign bone tumors making it a relatively rare form of bone tumor.[citation needed] ... Bone scintigraphy (bone scan) demonstrates abnormal radiotracer accumulation at the affected site, substantiating clinical ... Therefore, bone scans are useful only in conjunction with other radiologic studies and are not best used alone.[citation needed ...
Leukaemias are subdivided into lymphoid and myeloid neoplasms, depending on which bone marrow cells are cancerous. The myeloid ... In adults, blood cells are formed in the bone marrow, by a process that is known as haematopoiesis. In CMML, there are ... Bone marrow core biopsies may show a predominance of myelocytic and monocytic cells, abnormal localisation of immature ... The FAB criteria for diagnosis are as follows: Monocyte count >1x109/L 0-19% blasts in bone marrow 1x109/L No Philadelphia ...
While chondrosarcoma is the most common form of a secondary malignant bone neoplasm found in cases of Ollier disease, other ... Early detection and consistent and repeated monitoring is important in order to prevent and treat any potential bone neoplasms ... Clinical and radiological evaluations are conducted in order to detect the presence of bone neoplasms or lesions typically ... Abnormal bone growth such as shortening or thickening and deformity may be observed in patients of Ollier disease. These bone ...
Overall survival prognosis is about 30%. Deaths due to malignant neoplasms of the bones and joints account for an unknown ... usually associated with an underlying bone pathology such as Paget's disease of bone. Osteosarcoma is the most common bone ... Large doses of Sr-90, nicknamed bone seeker, increases the risk of bone cancer and leukemia in animals and is presumed to do so ... The tumor causes a great deal of pain, and can even lead to fracture of the affected bone. As with human osteosarcoma, bone ...
Other embolizations are also performed for symptom relief or prior to surgery to reduce bleeding Bone Cancer: bone metastases ... such as osteoporosis or underlying neoplasm. Analogous to vertebroplasty, the purpose of sacroplasty is to provide ... to stabilize the bone. These treatments may be palliatively for bone metastases pain or for some cases such as osteoid osteoma ... A needle is placed through the skin and into the bone under CT guidance and a polymethylmethacrylate mixture is injected into ...
In cases of a supposed myeloid neoplasm, a bone marrow biopsy will be performed utilizing cytogenetic analysis. This type of ... A bone marrow aspirate may be utilized to confirm an increase in basophils or significantly high numbers of precursors to the ... Elevation of basophils may also be representative of multiple other underlying neoplasms such as polycythemia vera (PV), ... The root cause of basophilia can be determined through a bone marrow biopsy, genetic testing to look for genetic mutations, or ...
It may also occur with fractures of the facial bones, neoplasms, during asthma attacks, when the Heimlich maneuver is used, and ...
T-Cell Lymphoblastic Leukemia (T-ALL) is a type of acute lymphoblastic leukemia with aggressive malignant neoplasm of the bone ... Bone marrow consists of a combination of solid and liquid components. Bone marrow aspiration and biopsies are typically done ... Acute Lymphoblastic Leukemia (ALL) is a condition where immature white blood cells accumulate in the bone marrow, subsequently ... Patients often present extensive bone marrow involvement, mediastinal mass, adenopathy, CNS involvement, and splenomegaly. ...
A phosphaturic mesenchymal tumor is an extremely rare benign neoplasm of soft tissue and bone that inappropriately produces ... Rowe PS, de Zoysa PA, Dong R, Wang HR, White KE, Econs MJ, Oudet CL (July 2000). "MEPE, a new gene expressed in bone marrow and ... Adult patients may present with worsening musculoskeletal symptoms, muscle weakness, myalgias, bone pains and fatigue which are ... Journal of Bone and Mineral Research. 22 (6): 931-937. doi:10.1359/jbmr.070304. PMID 17352646. Chong WH, Molinolo AA, Chen CC, ...
... system and intrathoracic organs 170 Malignant neoplasm of bone and articular cartilage 170.9 Malignant neoplasm of bone and ... 140 Malignant neoplasm of lip 141 Malignant neoplasm of tongue 142 Malignant neoplasm of major salivary glands 143 Malignant ... benign neoplasm of uterus 220 Benign neoplasm of ovary 221 Benign neoplasm of other female genital organs 222 Benign neoplasm ... neoplasm of oropharynx 147 Malignant neoplasm of nasopharynx 148 Malignant neoplasm of hypopharynx 149 Malignant neoplasm of ...
A juvenile active ossifying fibroma is a benign fibro-osseous neoplasm composed of mixture of stroma and bone characterized by ... MRI shows a variable finding depending on T1 or T2 weighted images, dependent on the amount of bone to fibrous connective ... Many times the curved-shaped bone fragments have a collagenous rim around them. Ossicles may fuse to form much large ... When performing imaging studies, bone windows in computed tomography studies are the best. The lesion is usually identified as ...
Macrosomia Macroglossia Advanced bone age Organomegaly Neonatal hypoglycemia Neoplasms Congenital diaphragmatic hernia ( ... One of the most noted features of OGS is the increased risk of neoplasms in certain OGSs. SGBS in particular has been found to ... Limb patterning and skeletal development may also go awry when GPC3 mutations inhibit regulations of responses to bone ...
... tracheal neoplasms MeSH C04.588.448.200 - bone marrow neoplasms MeSH C04.588.531.500 - mammary neoplasms, experimental MeSH ... skull base neoplasms MeSH C04.588.149.828 - spinal neoplasms MeSH C04.588.180.260 - breast neoplasms, male MeSH C04.588.180.390 ... bile duct neoplasms MeSH C04.588.274.120.250.250 - common bile duct neoplasms MeSH C04.588.274.120.401 - gallbladder neoplasms ... femoral neoplasms MeSH C04.588.149.721 - skull neoplasms MeSH C04.588.149.721.450 - jaw neoplasms MeSH C04.588.149.721.450.583 ...
... pseudogout Neoplasms Neurovascular disorders Bone and cartilage disorders Extraarticular disorders Bursitis/Tendinitis of the ... Altorok, Nezam; Nada, Shigeyuki; Nagaraja, Vivek; Kahaleh, Bashar (2016-06-15). "Chapter 17 - Epigenetics in Bone and Joint ... Bone, Spine: Revue du Rhumatisme. Elsevier. 81 (2): 118-124. doi:10.1016/j.jbspin.2014.01.001. PMID 24556284. Murphy, Kenneth; ...
... bone marrow neoplasms MeSH C15.378.420.155 - anemia, sickle cell MeSH C15.378.420.155.440 - hemoglobin sc disease MeSH C15.378. ... bone marrow neoplasms MeSH C15.378.190.625 - myelodysplastic syndromes MeSH C15.378.190.625.062 - anemia, refractory MeSH ... splenic neoplasms MeSH C15.604.744.742 - splenic rupture MeSH C15.604.744.742.500 - splenosis MeSH C15.604.744.909 - ...
... and hematopoietic neoplasms of bone. Bone tumors may be classified as "primary tumors", which originate in bone or from bone- ... Stage 1A bone cancer Stage 1B bone cancer Stage 2A bone cancer Stage 2B bone cancer Stage 3 bone cancer Treatment of bone ... Instead of amputation, the affected bone is removed and replaced in one of two ways: (a) bone graft, in which bone is taken ... One of the major concerns is bone density and bone loss. Non-hormonal bisphosphonates increase bone strength and are available ...
... will learn in depth about the pathology and treatment of various forms of primary benign and malignant neoplasms of the bones ... to the bones, which is much more common; these specialists deal mostly with primary bone tumors). The physician will study ... Due to the relative rarity of primary bone tumor in relation to other forms of cancer, there are fewer than two hundred ... it is advisable when confronted with primary malignancy of the bone to seek out the treatment of an orthopedic oncologist, due ...
Infiltrative, highly cellular spindled cell neoplasm is poorly circumscribed and unencapsulated. Bone destruction or invasion ... Definitions: A low-grade spindle-cell neoplasm of the sinonasal tract associated with overlying respiratory epithelium and ...
... a malignant neoplasm of bone Open Scripting Architecture, for AppleScript Open Services Access, a set of standards for mobile ...
The work of Aigner et al suggests that chondroblastoma should be reclassified as a bone-forming neoplasm versus a cartilaginous ... "Chondroblastoma of Bone." The Journal of Bone and Joint Surgery 82A.8 (2000): 1140-1145. Web. 6 Dec. 2015. Kurt, Ann-Marie, et ... However, local recurrence for long bone lesions is around 10%, with chondroblastoma in flat bones having higher recurrence and ... locally aggressive bone tumor that typically affects the epiphyses or apophyses of long bones. It is thought to arise from an ...
Bone defects or fractures can occur in a number of ways, including trauma, neoplasm, osteoporosis, or congenital disorders. ... Coating an implant with RGD has been shown to improve bone cell adhesion, proliferation and survival. In vivo studies of such ... Modifying a titanium implant surface with a protein containing RGD improved bone mineralization and implant integration and ... There is therefore considerable interest in developing tissue engineered bone constructs, which should encourage tissue ...
... is an uncommon myeloproliferative neoplasm (a type of chronic leukemia) in which the bone marrow makes too ... red cell mass arterial oxygen saturation abdominal ultrasound serum erythropoietin level bone marrow aspirate and trephine ... related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms ...
... neoplasms can be separated into Hürthle cell adenomas and carcinomas, which are respectively benign and malignant ... On few occasions, patients with Hürthle cell carcinoma have distant metastases in the lungs or surrounding bones. Hürthle cell ... Some scientists have identified these mutations as deletions in the mitochondrial DNA of Hürthle cells found in neoplasms and ... References for findings: - Ayana Suzuki, C.T., Andrey Bychkov, M.D., Ph.D. "Hürthle cell neoplasm". Pathology Outlines.{{cite ...
The skull bone structure can also be subject to a neoplasm that by its very nature reduces the volume of the intracranial ... Neoplasms will often show as differently colored masses (also referred to as processes) in CT or MRI results.[citation needed] ... Compared to MRI, a CT scan shows a more detailed image of the bone structures near the tumor and can be used to measure the ... More generally a neoplasm may cause release of metabolic end products (e.g., free radicals, altered electrolytes, ...
It is a typically benign and slow growing, but invasive neoplasm. Intraosseous tumors (tumors within the bone) are more common ... Like other odontogenic neoplasms, it is thought to arise from the epithelial element of the enamel origin. ...
Myung SK, Ju W, Kim SC, Kim H (October 2011). "Vitamin or antioxidant intake (or serum level) and risk of cervical neoplasm: a ... bone fractures, and (rarely) leakage of urine or feces from the vagina. Bleeding after douching or after a pelvic exam is a ...
The World Health Organization (2019) classified papillary neoplasms (i.e. benign or cancerous tumors) of the breast into 5 ... 1 to lung and 1 to bone. By the end of the study, 47 individuals had no evidence of disease and 2 had died of unknown causes. ... Brogi E, Krystel-Whittemore M (January 2021). "Papillary neoplasms of the breast including upgrade rates and management of ... Tay TK, Tan PH (June 2021). "Papillary neoplasms of the breast-reviewing the spectrum". Modern Pathology. 34 (6): 1044-1061. ...
... syndrome Cystathionine beta synthetase deficiency Cystic adenomatoid malformation of lung Cystic angiomatosis of bone, diffuse ... Carrington syndrome Cartilage hair hypoplasia like syndrome Cartilage-hair hypoplasia Cartilaginous neoplasms Cartwright-Nelson ... hypoxia Cerebral malformations hypertrichosis claw hands Cerebral palsy Cerebral thrombosis Cerebral ventricle neoplasms ... dysplasia micrognathia absent thumbs Cloacal exstrophy Clonal hypereosinophilia Clouston syndrome Cloverleaf skull bone ...
... is a new piece of bone usually growing on another piece of bone, typically the skull. It is a benign tumor. When the bone tumor ... Osteoma represents the most common benign neoplasm of the nose and paranasal sinuses. The cause of osteomata is uncertain, but ... "Management of a Large Frontoethmoid Osteoma with Sinus Cranialization and Cranial Bone Graft Reconstruction". International ... grows on other bone it is known as "homoplastic osteoma"; when it grows on other tissue it is called "heteroplastic osteoma". ...
Dahlin DC: Bone Tumors: General Aspects and an Analysis of 2276 Cases, C.C. Thomas, Springfield, IL, 1957. Unni KK, Inwards CY ... but began to develop special expertise in neoplasms of the skeletal system. No one had previously studied such lesions ... Ayala, Alberto G. (1988). "Bone tumors, fourth edition. Edited by David C. Dahlin, MD, and Krishnan K. Unni, MB, BS, 522 pp, ... Dahlin's opinion was sought internationally on a huge number of challenging bone tumor cases, not only for advice on pathologic ...
Certain neoplasms can spread into the infratemporal fossa. This can be surgically removed through the middle cranial fossa. The ... It is not fully enclosed by bone in all directions. It contains superficial muscles, including the lower part of the temporalis ... posteriorly, by the tympanic part of the temporal bone, and the spina angularis of the sphenoid. superiorly, by the greater ... This also contains the lingula, a triangular piece of bone that overlies the mandibular foramen antero-medially. Finally, the ...
A bone marrow biopsy provides a sample of bone marrow, usually from the lower back of the pelvis bone. The sample is extracted ... ISBN 978-0-7817-5007-3. Frequency of lymphoid neoplasms. (Source: Modified from WHO Blue Book on Tumour of Hematopoietic and ... Bone marrow tumour cells express the following antigen targets CD20 (98.3%), CD22 (88.3%), CD40 (83.3%), CD52 (77.4%), IgM ( ... Autologous bone marrow transplantation is a treatment option. Zanubrutinib is indicated for the treatment of adults with ...
Bone scans should reveal osteoblastic appearance due to increased bone density in the areas of bone metastasis-the reverse of ... "Male Genitals - Prostate Neoplasms". Pathology study images. University of Virginia School of Medicine. Archived from the ... bones of the spine), pelvis, or ribs. Spread of cancer into other bones such as the femur is usually to the part of the bone ... Sclerosis of the bones of the thoracic spine due to prostate cancer metastases (CT image) Sclerosis of the bones of the ...
miR-708 has been implicated in the bone-specific Ewing's sarcoma. Upregulation of the DNA repair protein EYA3 in this tumour is ... "miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets ...
... neoplasm protein - Nernst equation - nerve - nerve growth factor - nerve growth factor receptor - nerve tissue protein - nerve ... bone morphogenetic protein - bradykinin - bradykinin receptor - BRCA1 - buffer solution C-terminus - C4 photosynthesis - ...
The extracavitary tumors may develop in lymph nodes, bone, bone marrow, the gastrointestinal tract, skin, spleen, liver, lungs ... This lymphoma also belongs to a group of lymphoid neoplasms with plasmablastic differentiation that involve malignant ... List of hematologic conditions Chen BJ, Chuang SS (March 2020). "Lymphoid Neoplasms With Plasmablastic Differentiation: A ... "Molecular genetic analysis of three AIDS-associated neoplasms of uncertain lineage demonstrates their B-cell derivation and the ...
... requiring the extraction of bone marrow samples from the hip bone to determine the presence of lymphoma cells in bone marrow. ... "The 2016 revision of the World Health Organization classification of lymphoid neoplasms". Blood. 127 (20): 2375-2390. doi: ... Bone marrow biopsy is used to show the extent of disease, known as staging in pathology. The process takes about 10-15 minutes ... "Lymphoma Action , Bone marrow biopsy". Lymphoma Action. Retrieved 2020-04-26. "Understanding Mature T-Cell Lymphoma - Fact ...
As studies of biological samples (including bone, thyroid glands and other tissues) have been undertaken, it has become ... Several severe adverse health effects, such as an increased incidence of cancers, thyroid diseases, CNS neoplasms, and possibly ...
... and bone marrow and evidence (i.e. cytopenias) of bone marrow failure. Blastic plasmacytoid dendritic cell neoplasm has a high ... Blastic plasmacytoid dendritic cell neoplasm is a rare type of myeloid cancer in which malignant pDCs infiltrate the skin, bone ... The monocytes in turn are formed from stem cells in the bone marrow. Monocyte-derived dendritic cells can be generated in vitro ... Wang S, Wang X, Liu M, Bai O (April 2018). "Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel ...
Renal epithelial neoplasms have characteristic cytogenetic aberrations that can aid in classification. See also Atlas of ... Correlation of prognosis with bone marrow cytogenetic finding in acute lymphoblastic leukemia Unclassified ALL is considered to ... "Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms." Nature 13 Aug 2009; 460, 904-909. Gondek LP, Tiu R, ... Malignant rhabdoid tumors are rare, highly aggressive neoplasms found most commonly in infants and young children. Due to their ...
Bone tumors were located in the femurs, mandible, maxilla, tibias, or in one case each the hard palate and sacrum. In other ... Baranov E, Hornick JL (March 2020). "Soft Tissue Special Issue: Fibroblastic and Myofibroblastic Neoplasms of the Head and Neck ... Zhao KY, Yan X, Yao PF, Mei J (September 2021). "Malignant fibrous histiocytoma of the bone in a traumatic amputation stump: A ... were in bone. Overall, 51.5% of their tumors were in the head and neck areas (most commonly the tongue, followed by the larynx ...
... and play a role in limiting formation of bone marrow plasma cells secreting IgG2a and IgG2b. The CD79a protein is present on ... and is also present in virtually all B-cell neoplasms, including B-cell lymphomas, plasmacytomas, and myelomas. It is also ... "Cytoplasmic Ig alpha serine/threonines fine-tune Ig alpha tyrosine phosphorylation and limit bone marrow plasma cell formation ...
Claims that breaking bones resulted in bone cancer, for example, have not been proven. Similarly, physical trauma is not ... They form a subset of neoplasms. A neoplasm or tumor is a group of cells that have undergone unregulated growth and will often ... For painful bone metastasis, it has been found to be effective in about 70% of patients. Surgery is the primary method of ... Sarcoma: Cancers arising from connective tissue (i.e. bone, cartilage, fat, nerve), each of which develops from cells ...
It is suggested that the presence of these fusion genes indicates that SEC is a true neoplasm. Unicameral bone cysts are found ... Bone Grafting: Bone grafting is proceeded with after curettage; the empty cavity is transplanted with donor bone tissue, bone ... 2020). "3. Bone tumours: simple bone cyst". Soft Tissue and Bone Tumours: WHO Classification of Tumours. Vol. 3 (5th ed.). Lyon ... A unicameral bone cyst, also known as a simple bone cyst, is a cavity filled with a yellow-colored fluid. It is considered to ...
This type of mutation in a dividing stem cell in the bone marrow leads to adult leukemia Philadelphia Chromosome is an example ... Mitchell RS, Kumar V, Abbas AK, Fausto N (2007). "Chapter 20 - Neoplasms of the Thyroid". Robbins Basic Pathology (8th ed.). ...
CD10+ differentiates mucinous cystic neoplasms (CD10+/CK20+) from intraductal papillary mucinous neoplasm of branch duct type ( ... and dendritic cells arise from a common bone marrow progenitor cell subset". Immunity. 3 (4): 459-73. doi:10.1016/1074-7613(95) ... Murali R, Delprado W (2005). "CD10 immunohistochemical staining in urothelial neoplasms". Am. J. Clin. Pathol. 124 (3): 371-9. ... and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms". ...
Bone marrow examination may reveal increases in eosinophils and mast cells but usually does not contain elevated numbers of ... Vega F, Medeiros LJ, Bueso-Ramos CE, Arboleda P, Miranda RN (2015). "Hematolymphoid neoplasms associated with rearrangements of ... Rather, definitive results are obtained by detecting the presence of the FIP1L1-PDGFRA fusion gene in the blood and/or bone ... While the success of Gleevec in treating the myeloproliferative neoplasm/myeloblastic leukemia or T-lymphoblastic leukemia/ ...
They are only attached to the skin, not to the underlying muscle and bone, so their only physical effects on the deer stem from ... Cutaneous fibromas (also known as deer warts) are common neoplasms occurring in wild and domestic deer of many species and are ...
FGF23 is also overproduced by some types of tumors, such as the benign mesenchymal neoplasm phosphaturic mesenchymal tumor ... Dance A (23 February 2022). "Fun facts about bones: More than just scaffolding". Knowable Magazine. doi:10.1146/knowable-022222 ... December 2017). "MicroRNA expression in a phosphaturic mesenchymal tumour". Bone Reports. 7: 63-69. doi:10.1016/j.bonr.2017.09. ...
Ureteral neoplasm, a type of tumor that can be primary, or associated with a metastasis from another site Urethral cancer, ... bone, etc.) Other classifications of transitional cell cancer of the ureter include localized, regional, metastatic, and ...
Often, since facial neoplasms have such an intimate relationship with the facial nerve, removing tumors in this region becomes ... Inflammation from the middle ear can spread to the canalis facialis of the temporal bone - through this canal travels the ... While this will inevitably lead to facial paralysis, safe removal of a malignant neoplasm is vital for patient survival. After ... Physical trauma, especially fractures of the temporal bone, may also cause acute facial nerve paralysis. Understandably, the ...
In light of new therapies such as targeted agents, the role of bone marrow transplants is decreasing. Bone marrow transplants ... Hairy cell leukemia is also a neoplasm of B lymphocytes, but the neoplastic cells have a distinct morphology under the ... CLL results in the buildup of B cell lymphocytes in the bone marrow, lymph nodes, and blood. These cells do not function well ... Chronic lymphocytic leukemia (CLL) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white ...
... no evidence of bone loss over last five years Grade B: Moderate progression; < 2mm of bone loss over last five years Grade C: ... induced Genetic/developmental disorders Specific infections Inflammatory and immune conditions Reactive processes Neoplasms ... periodontal surgery may be needed to stop progressive bone loss and regenerate lost bone where possible. Many surgical ... In its more serious form, called periodontitis, the gums can pull away from the tooth, bone can be lost, and the teeth may ...
Histological typing of bone tumours / F. Schajowicz, in collaboration with pathologists in 9 countries  ...
... and other myeloproliferative neoplasms (MPNs) is linked to constitutive activation of the JAK-STAT pathway, JAK inhibitors have ... Bone marrow-specific loss of ABI1 induces myeloproliferative neoplasm with features resembling human myelofibrosis Blood. 2018 ... Here we present data showing that bone marrow-specific deletion of Abi1 in a novel mouse model leads to development of an MPN- ... Although the pathogenesis of primary myelofibrosis (PMF) and other myeloproliferative neoplasms (MPNs) is linked to ...
Malignant bone marrow disease: New hope for MPN patients: Myeloproliferative neoplasms (MPNs) - a group of rare but malignant ... Home » Health News » Malignant bone marrow disease: New hope for MPN patients: Myeloproliferative neoplasms (MPNs) - a group of ... bone marrow disorders. 02/08/2019. MPNs are a group of rare, malignant diseases of the bone marrow involving the production of ... MPNs are caused by genetic changes (mutations) of the hematopoietic cells in the bone marrow that are acquired spontaneously, ...
"Bone Neoplasms" by people in this website by year, and whether "Bone Neoplasms" was a major or minor topic of these ... "Bone Neoplasms" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical Subject ... Below are the most recent publications written about "Bone Neoplasms" by people in Profiles. ... Below are MeSH descriptors whose meaning is more general than "Bone Neoplasms". ...
Radiology of bone tumors and allied disorders / Daniel Wilner ; collaborators, Harry K. Genant ... [et al.] by Wilner, Daniel ... Histological classification of bone and joint tumors of domestic animals / compiled and reviewed by M. V. Slayter ... [et al.] ... Histological typing of bone tumours / F. Schajowicz, in collaboration with pathologists in 9 countries. by Schajowicz, F , ... WHO classification of tumours of soft tissue and bone / edited by Christopher D.M. Fletcher ... [et al] by Fletcher, ...
Learn how bone cancer is diagnosed and treated. ... Bone cancer comes in three types: Osteosarcoma, Chondrosarcoma ... ClinicalTrials.gov: Bone Neoplasms (National Institutes of Health) * ClinicalTrials.gov: Osteosarcoma (National Institutes of ... Primary Bone Cancer (National Cancer Institute) Also in Spanish * What Is Bone Cancer? (American Cancer Society) Also in ... Bone Cancer Stages (American Cancer Society) Also in Spanish * Bone Scan (Mayo Foundation for Medical Education and Research) ...
The pathology of head and neck tumors: Neoplasms of cartilage, bone, and the notochord, part 7. Head & Neck Surgery. 1980 Jan 1 ... Batsakis, J. G., Solomon, A. R., & Rice, D. H. (1980). The pathology of head and neck tumors: Neoplasms of cartilage, bone, and ... The pathology of head and neck tumors : Neoplasms of cartilage, bone, and the notochord, part 7. / Batsakis, John G.; Solomon, ... Batsakis, John G. ; Solomon, Alvin R. ; Rice, Dale H. / The pathology of head and neck tumors : Neoplasms of cartilage, bone, ...
Malignant neoplasm of bone and articular cartilage, unspecified. C44. Other and unspecified malignant neoplasm of skin. ... Encounter for aftercare following bone marrow transplant. Z48.810. Encounter for surgical aftercare following surgery on the ...
Bone Cancer 7 studies. 937 studies. Bone Neoplasms. 4 studies. 370 studies. ...
Nocturnal pain suggests osteoid osteoma or other bone neoplasms.. Growing pains, a diagnosis of exclusion, requires that ... Easy bruising, weight loss, or bone pain may be seen with neoplastic or other infiltrative bone marrow disease. ... Bone infection and the limping child in the accident & emergency department: a diagnosis to be considered. Arch Emerg Med. 1992 ... Extensive bone marrow edema is present in the femoral metaphysis, with edema in the surrounding soft tissues. ...
Long Non-Coding RNA HULC Promotes Progression of Bone Neoplasms Tao Zhang, Chun-You Wan, [...] Xiao-Long Mei, Peng Jia, Ming- ... Peroxiredoxin 1 (PRDX1) Suppresses Progressions and Metastasis of Osteosarcoma and Fibrosarcoma of Bone Yongxiang Wang, Mingfa ...
Bone lesions may be mistaken for tubercular cold abscess or neoplasm.. Previous ... Bone lesions develop in 5%-10% of patients and are usually osteolytic or resemble cold abscesses. These lesions may be confused ... The organs most often involved include the CNS, bones, prostate, eyes, and skin. Prior to the discovery of amphotericin B in ... Bone lesions are usually osteolytic and may be misinterpreted as neoplastic lesions or osseous tuberculosis. ...
Care guide for Bone Metastasis (Discharge Care). Includes: possible causes, signs and symptoms, standard treatment options and ... Learn more about Bone Metastasis. Treatment options. *Medications for Neoplasm of Bone ... Bone metastasis often happens in the spine, upper arm or leg bone, ribs, hips, or skull. Cancer that spreads to a bone can ... Alcohol can decrease bone mineral density and weaken your bones. Limit alcohol to 2 drinks per day if you are a man. Limit ...
Bone Marrow Neoplasms. 1. 2019. 108. 0.180. Why? Thiophenes. 1. 2021. 600. 0.150. Why? ...
Bone Tissue Neoplasms + chondroma + clear cell sarcoma + connective tissue benign neoplasm + A musculoskeletal system benign ... mesenchymal tissue neoplasm ; neoplasm of soft tissue ; neoplasm of soft tissues ; soft tissue benign neoplasm ; tumor of the ... connective tissue benign neoplasm (DOID:0060123). Annotations: Rat: (32) Mouse: (32) Human: (33) Chinchilla: (31) Bonobo: (30) ...
Bone marrow findings in Erdheim-Chester disease: increased prevalence of chronic myeloid neoplasms (928 Online Views) Gaurav ... Myeloid Neoplasms. Loss of RAF kinase inhibitor protein is involved in myelomonocytic differentiation and aggravates RAS-driven ... Myeloproliferative Neoplasms. Molecular quantification of tissue disease burden is a new biomarker and independent predictor of ... Characterization of the phenotype of human eosinophils and their progenitors in the bone marrow of healthy individuals (7969 ...
2130.0 Other malignant neoplasms Includes: Metastatic carcinoma Brain tumor Bone cancer Carcinoma-in-situ, NOS. 2135.0 ... 2150.0 Neoplasm of uncertain nature Excludes: Neoplasm, NOS Brain tumor (2130.0). ENDOCRINE, NUTRITIONAL, AND METABOLIC ... NEOPLASMS (2100-2199). Malignant neoplasms:. 2100.0 Cancer, gastrointestinal tract Includes: Esophagus Stomach Small intestine ... Benign and uncertain nature neoplasms:. 2140.0 Fibroids and other uterine neoplasms Includes: Myoma Leiomyomata Cervical polyp ...
Myeloproliferative neoplasms (MPNs): MPNs are chronic cancers of the bone marrow and blood. While they are not classified as ... Most develop in the bone marrow, the spongy interior of bones that contains immature stem cells. ... Blastic plasmacytoid dendritic cell neoplasm (BPDCN) BPDCN is an aggressive subtype of acute leukemia that impacts ... Leukemia in children is caused by a mutation in the DNA of a bone marrow stem cell at some point in its development. The cell ...
d) Other specified malignant bone tumors. (d.1) Malignant fibrous neoplasms of bone. 8810, 8811, 8818, 8823, 8830. 400-419. 3. ... c) Ewing tumor and related sarcomas of bone. (c.1) Ewing tumor and Askin tumor of bone. 9260. 400-419, 760-768, 809. 3. 048. ... e) Other specified intracranial and intraspinal neoplasms. (e.1) Pituitary adenomas and carcinomas. 8158, 8290. 751. 0-1, 3. ... X. Germ Cell Tumors, Trophoblastic Tumors And Neoplasms Of Gonads. (a) Intracranial and intraspinal germ cell tumors. ...
Surgical resection and reconstruction for low grade bone sarcoma in the metaphysis of the long bone remains challenging. We ... allograft bone12, bone cement4, autograft bone11, 25, bone transport26 and tumor bone inactivation and replantation27. Although ... Subsequently, the inactivated bone tissue was transplanted back to the bone defect site, and the appropriate length of the bone ... Therefore, inactivated bone tumor allow integration of grafted bone and autogenous bone, and retains the shape and mechanical ...
The bone marrow was slightly hypoplasia without evidence of myeloproliferative neoplasms. Upper gastrointestinal endoscopy ... Bone marrow examination revealed de novo acute myeloid leukemia. Although portal hypertension has been reportedly associated ...
Neoplasm Metastasis Medicine & Life Sciences 37% * Bone and Bones Medicine & Life Sciences 36% ... Long-term follow-up showed no AML, MDS, or new primary bone cancer; secondary non-treatment-related malignancies occurred in ... Long-term follow-up showed no AML, MDS, or new primary bone cancer; secondary non-treatment-related malignancies occurred in ... Long-term follow-up showed no AML, MDS, or new primary bone cancer; secondary non-treatment-related malignancies occurred in ...
Aneurysmal bone cyst (ABC) is a benign, reactive, non-neoplastic, proliferative, highl ... Aggressive "benign" primary spine neoplasms: osteoblastoma, aneurysmal bone cyst, and giant cell tumor. Spine (Phila Pa 1976) ... Aneurysmal bone cyst of the extremities. Factors related to local recurrence after curettage with a high-speed burr. J Bone ... Aneurysmal bone cyst of the spine. J Bone Joint Surg Am 1985;67:527-31.. * Cited Here ...
Breast Neoplasms Medicine & Life Sciences 51% * Neoplasm Metastasis Medicine & Life Sciences 50% ... was significantly increased in plasma of patients with bone metastasis compared with patients without bone metastasis (P , ... was significantly increased in plasma of patients with bone metastasis compared with patients without bone metastasis (P , ... was significantly increased in plasma of patients with bone metastasis compared with patients without bone metastasis (P , ...
Classified as one of the myeloid neoplasms with germline predisposition and other organ dysfunction in the revised 2016 WHO ... Myeloid neoplasms mainly involve the peripheral blood and bone marrow * Many other organs other than bone marrow (e.g. ear, ... Bone marrow neoplastic. Bone marrow - neoplastic myeloid. Myeloid neoplasms with germline predisposition and other organ ... Peripheral blood and bone marrow can be affected by myeloid neoplasm or other hematological malignancies; they should be used ...
A. Bone contusions. B. Metastatic disease. C. Infection. D. Medullary infarction of bone. E. Primary neoplasm of bone. ... The term bone infarct can also be applied. These terms refer to abnormalities in the diaphyseal and metaphyseal regions of bone ... A bone infarct occurs when the blood supply is disrupted. There are many causes of bone infarcts to include trauma, ... A primary lesion of the bone is unlikely to affect multiple bones. Additionally there is no suggestion of new bony growth or ...
... neoplasm of bone. In other words, change the 20 to V. NOTE: The use of prefixes facilitates the calculation of percent ... Other malignant and unspecified neoplasms Includes: Metastic carcinoma Brain tumor Bone cancer 2135.0 Hodgkins disease, ... Neoplasms Malignant Neoplasms 2100.0 Cancer, gastrointestinal tract Includes: Esophagus Stomach Small intestine Colon 2105.0 ... Fibroids and other uterine neoplasms Includes: Myoma Leiomyomata Cervical polyp Nabothian cyst 2145.0 Other benign neoplasms ...
Heterozygous variants in bone marrow failure and myeloid neoplasms. Marsh, J. C. W., Gutierrez-Rodrigues, F., Cooper, J., Jiang ... Bone marrow failure: causes and complications. Kulasekararaj, A. G., Mufti, G. J. & Marsh, J. C. W., May 2021, In: Medicine ( ... Bone Marrow Stem Cells from Patients with Myelodysplastic Syndrome (MDS) Engraft and Migrate in-between the Humanized Niches in ... Novel ADA2 mutation presenting with neutropenia, lymphopenia and bone marrow failure in patients with deficiency in adenosine ...
  • Optimization and Characterization of a Bone Culture Model to Study Prostate Cancer Bone Metastasis. (viictr.org)
  • Bone metastasis is cancer that starts in one area and then spreads to a bone. (drugs.com)
  • Background: Breast cancer bone metastasis is a complication that significantly compromises patient survival due, in part, to the lack of disease-specific biomarkers that allow early and accurate diagnosis. (elsevier.com)
  • Methods: Using mass spectrometry protein profiling, plasma samples were screened from three independent breast cancer patient cohorts with and without clinical evidence of bone metastasis. (elsevier.com)
  • Conclusions: These data show that PTHrP(12-48) circulates in plasma of patient with breast cancer and is a novel and predictive biomarker of breast cancer bone metastasis. (elsevier.com)
  • Importantly, the clinical measurement of PTHrP(12-48) in combination with NTx improves the detection of breast cancer bone metastasis. (elsevier.com)
  • Impact: In summary, we present the first validated, plasma biomarker signature for diagnosis of breast cancer bone metastasis that may improve the early diagnosis of high-risk individuals. (elsevier.com)
  • It then discusses the important biochemical aspects of pulmonary and prostatic neoplasms, including the serum acid and alkaline phosphatase activities of prostatic carcinoma. (elsevier.com)
  • Osseous solitary plasmacytoma of bone is a localized bone tumor of plasma cells, without evidence of plasma cell myeloma or marrow plasmacytosis. (medscape.com)
  • From January 2017 to August 2019, ten patients with low-grade malignant bone tumor in metaphysis of the limbs were treated with hemicortical resection using 3D printing guide plate and biological reconstruction. (researchsquare.com)
  • Nevertheless, hemiexcision of the tumor bone with inactivated tumor bone replantation is a valuable surgical procedure for low-grade malignant bone tumors without the medullary cavity or with only one side of the cortical bone. (researchsquare.com)
  • Besides, autologous tumor bone inactivation technology preserves the bone integrity of the patients, kills tumor cells, and reconstructs bone defects. (researchsquare.com)
  • Therefore, in the past three years, we used 3D printed osteotomy guide plate to assist hemibonectomy for low-grade malignant bone tumors of extremities to treat 10 patients through tumor bone resection and routine tumor bone inactivation and replantation for bone defect reconstruction. (researchsquare.com)
  • We also assumed that the corresponding 3D-printed osteotomy guide plate can aid in accurately performing the resection of tumor bone. (researchsquare.com)
  • This tumor bone can be dense and well-defined but more often is amorphous and often not associated with underlying normal bone (aggressive). (vin.com)
  • In this retrospective study of small bone tumors over the period of five years, the commonest tumor encountered was enchondroma. (who.int)
  • Plain radiographs are the usual method to establish the diagnosis and evaluate differential diagnoses in the study of bone tumor pathology. (bvsalud.org)
  • OBJECTIVE: To recognize the frequency of radiographic characteristics and associate them with bone tumor pathology. (bvsalud.org)
  • METHOD: Radiographic data were collected from 132 patients with tumor pathology confirmed by biopsy from bone tumors service of the Traumatology and Orthopedics Hospital Unidades Médicas de Alta Especialidad Dr. Victorio de la Fuente Narváez, Instituto Mexicano del Seguro Social, Ciudad de México, during 2019. (bvsalud.org)
  • INTRODUCCIÓN: El osteosarcoma es el tumor óseo maligno más común en la niñez y la adolescencia. (bvsalud.org)
  • By definition, the medullary canal of the affected bone and the canal of the tumor are connected. (medscape.com)
  • Desmoplastic fibroma (DF) of the bone is a rare locally aggressive tumor usually occurring in adolescents and young adults. (elsevier.com)
  • Tumors or cancer located in bone tissue or specific BONES. (viictr.org)
  • This is especially true for tumors of bone, cartilage, and the remnants of the notochord. (elsevier.com)
  • Rice, Dale H. / The pathology of head and neck tumors : Neoplasms of cartilage, bone, and the notochord, part 7 . (elsevier.com)
  • Here, we demonstrate that the 3D printing osteotomy guide plate assisted hemicortical bone resection is a beneficial strategy to effectively resect the primary low-grade malignant bone tumors in the metaphysis of long bone and restore excellent joint function. (researchsquare.com)
  • Paracortical osteosarcoma and highly differentiated chondrosarcoma are the most prevalent primary bone tumors 1 , 2 . (researchsquare.com)
  • With a distinct emphasis on bone tumors of adjacent joints, this can preserve joints and maximize joint function 12 . (researchsquare.com)
  • An international myeloma meeting entitled "Challenging the current approaches to multiple myeloma- and other cancer-related bone diseases: from bisphosphonates to targeted therapy" was held in Freiburg, Germany in July 2011 to discuss novel insights into and approaches to myeloma bone disease and other bone-seeking tumors. (elsevier.com)
  • A major unsolved problem in orthopedic surgery is how to manage massive bone defects after tumors, osteomyelitis or non-unions. (lu.se)
  • A mixed radiographic pattern may develop with osteomyelitis, bone tumors and to some extent, normal bone healing. (vin.com)
  • This pattern may be seen with developmental or inactive traumatic disorders that affect bone modeling, malunion fractures and some benign bone tumors. (vin.com)
  • Biochemistry of Human Cancer focuses on advances in the application of biochemistry to the study of human cancers, such as neoplastic immunoglobulinopathies, cancer of the bladder, tumors of the neural crest, leukemias and lymphomas, and neoplasms of the bone. (elsevier.com)
  • The remaining chapters look at the role of enzymes and immunoglobulins in cancer, the tryptophan metabolism in cancer of the bladder and the carcinoid syndrome, the link between amino acid metabolism and tumors of the neural crest, and the neoplasms of the digestive tract and the accessory organs (pancreas and liver). (elsevier.com)
  • Osteomas are benign tumors of growing bone that present in a periosteal or endosteal form and commonly affect the craniofacial skeleton bones, being rarely found in other parts of the body. (bvsalud.org)
  • IMSEAR at SEARO: Primary tumors of small bones: a clinicopathological and radiological study. (who.int)
  • Primary small bone tumors are rare. (who.int)
  • These tumors most commonly occur in the mandibles and metaphyses of long bones but are extremely rare in small bones, often resulting in diagnostic problems. (elsevier.com)
  • The role of electron microscopy in characterization of uncommon epithelial pulmonary neoplasms, metastatic neoplasms to and from lung and other tumors, including mesenchymal neoplasms. (uab.edu)
  • Although the pathogenesis of primary myelofibrosis (PMF) and other myeloproliferative neoplasms (MPNs) is linked to constitutive activation of the JAK-STAT pathway, JAK inhibitors have neither curative nor MPN-stem cell-eradicating potential, indicating that other targetable mechanisms are contributing to the pathophysiology of MPNs. (nih.gov)
  • MPNs are a group of rare, malignant diseases of the bone marrow involving the production of an excess of red blood cells, white blood cells and/or platelets. (ehealthweek2010.org)
  • MPNs are caused by genetic changes (mutations) of the hematopoietic cells in the bone marrow that are acquired spontaneously, due to certain genetic predispositions or as a result of environmental influences. (ehealthweek2010.org)
  • What are myeloproliferative neoplasms (MPNs)? (voicesofmpn.com)
  • Myeloproliferative neoplasms (MY-ah-lo-pro-LIF-er-uh-tiv NEE-o-plaz-uhms), or MPNs, are a group of rare, chronic blood cancers in which a person's bone marrow does not function properly. (voicesofmpn.com)
  • Myeloproliferative neoplasms, or MPNs, are a group of rare, chronic blood cancers in which a person's bone marrow does not function properly. (voicesofmpn.com)
  • Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. (viictr.org)
  • Surgical resection and reconstruction for low grade bone sarcoma in the metaphysis of the long bone remains challenging. (researchsquare.com)
  • Retinoic Acid Receptor Activation Reduces Metastatic Prostate Cancer Bone Lesions by Blocking the Endothelial-to-Osteoblast Transition. (viictr.org)
  • Plasma cell lesions are the neoplastic (clonal) proliferation of plasma cells involving single bones (plasmacytoma) or multiple bones (multiple myeloma). (medscape.com)
  • In either form of plasma cell myeloma, immune dysfunction, cytopenias and lytic bone lesions occur as a result of direct cellular interactions (cytokines, growth factors) and/or mass effect. (medscape.com)
  • Plasma cell myeloma presents with generalized marrow involvement, with or without lytic lesions of bone. (medscape.com)
  • Asymptomatic plasma cell myeloma is a plasma cell neoplasm defined by the presence of serum monoclonal protein of 3.0 gm/dL or greater (by electrophoresis) and/or clonal plasma cells in the bone marrow of 10% or greater, without evidence of end-organ damage (hypercalcemia, renal insufficiency, anemia, lytic lesions of bone). (medscape.com)
  • Symptomatic plasma cell myeloma is a plasma cell neoplasm defined as the presence of end-organ damage (hypercalcemia, renal insufficiency, anemia, lytic lesions of bone) in a patient with a monoclonal protein (of any amount) and clonal plasma cells in the bone marrow (of any amount) or plasmacytoma. (medscape.com)
  • Hypercalcemia results from the increased osteoclastic activity, with resultant lytic bone lesions and pathologic fractures (see the image below). (medscape.com)
  • It usually arises from long bones, but approximately 12% to 30% of lesions involve the spine. (lww.com)
  • Despite the limited responses of bone to insult, lesions can often be classified by disease category which can, in turn, be used to establish a definitive or differential diagnosis (Table 1). (vin.com)
  • A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. (ebi.ac.uk)
  • CONCLUSIONS: Poorly defined intraosseous blast lesions of bone lineage, periosteal reaction, and moth-eaten or permeative pattern of destruction are associated with malignant lesions. (bvsalud.org)
  • Although this technique has primarily been described in literature to treat bone marrow lesions (BMLs) in the knee joint, this technique has recently been applied to the foot and ankle with comparably successful outcomes. (faoj.org)
  • These abnormalities can be identified both histologically and on magnetic resonance imaging (MRI) as bone marrow lesions (BMLs) [4-7]. (faoj.org)
  • Plasma cell myeloma (multiple myeloma, myelomatosis, medullary plasmacytoma) is a bone marrow-based, malignant disorder of postgerminal center B-cells that is characterized by a clonal proliferation of plasma cells, with associated serum and/or urine monoclonal proteins. (medscape.com)
  • Multiple myeloma (MM) is a hematologic neoplasm characterized by the monoclonal proliferation of bone marrow plasma cells [ 1 ]. (cdlib.org)
  • Multiple myeloma (MM) is an incurable cancer in which uncontrolled plasma cell proliferation disrupts the bone marrow environment and impairs immune function. (hrb.ie)
  • This cohort also includes patients with myelodysplastic syndrome (MDS)/myeloproliferative neoplasm (MPN) overlap syndromes, excluding juvenile myelomonocytic leukemia (JMML). (clinicaltrials.gov)
  • It has also been described infrequently in other myeloid neoplasms, including chronic myelomonocytic leukemia and myelodysplastic syndrome. (marshfieldlabs.org)
  • A musculoskeletal system benign neoplasm that is located_in connective tissue. (mcw.edu)
  • BACKGROUND: In Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial, radium-223 versus placebo prolonged overall survival with favorable safety in castration-resistant prostate cancer patients with symptomatic bone metastases. (qub.ac.uk)
  • Another two patients were diagnosed with both bone and lung metastases, only one of them underwent amputation. (manchester.ac.uk)
  • The book explains the metabolism of purines and pyrimidines in cancer, hypercalcemia in neoplastic disease without evidence of bone metastases, and neoplasms of other organs, such as the pituitary gland, thyroid, testis, and adrenal cortex. (elsevier.com)
  • Antiresorptive drugs operate in the bone metabolism modulation and are widely used in the treatment of bone metastases and bone losses related to hormonal deficiency. (bvsalud.org)
  • Even if at initial stages a tumour does not seem aggressive, its central location in proximity with several other organs makes it very dangerous: the most common metastases are in the lymph nodes and in the lungs (55%), liver and bones (33%), followed by the other kidney, the brain, the spleen, the colon and the skin. (lugnani.com)
  • IDH mutations are seen in 50% of chondrosarcomas, which represent approximately 25% of malignant bone neoplasms. (curesarcoma.org)
  • It presents images related to blood cells, bone marrow and hematologic diseases and neoplasms. (bvsalud.org)
  • A decrease in bone mineral may be generalized as with certain metabolic bone diseases such as 2° hyperparathyroidism, regional as occurs with disuse atrophy, or focal as occurs with many neoplasms. (vin.com)
  • Diseases emerging from bone marrow analyses-such as blood cancers-can be difficult to distinguish from a wide variety of noncancer causes, and often additional testing and data integration is required beyond morphologic evaluation of the bone marrow," explains Cordelia E. Sever, MD, FCAP, a hematopathologist at Presbyterian Hospital, Albuquerque, N.M. (medindia.net)
  • 50% of HIV deaths are caused by either coinfection or age-associated non-infectious chronic comorbidities, most notably vascular diseases, hypertension, lipid disorders, diabetes mellitus, chronic kidney disease (CKD), with or without dialysis, malignancies, and bone disorders. (medscape.com)
  • Get the latest scientific news and resources on diseases of the bones, joints, muscles, and skin from the NIAMS. (nih.gov)
  • [ 1 ] Extraosseous solitary plasmacytoma of bone is a localized, soft-tissue plasma cell neoplasm that occurs in a location other than the bone and does not have evidence of plasma cell myeloma or marrow plasmacytosis. (medscape.com)
  • For safe surgical boundaries, the hemibone resection strategy should retain more normal bone tissue as possible, thus providing favorable conditions for the reconstruction of the bone defects for the rapid postoperative recovery 9 - 11 . (researchsquare.com)
  • T he Smart Bone Project , focuses on in situ tissue engineering of bone -not in the lab, but in the patient . (lu.se)
  • Bone marrow is a spongy tissue inside of the bone, and is the primary place where blood cells are made. (voicesofmpn.com)
  • WHO Classification of Tumours of Soft Tissue and Bone. (who.int)
  • Metastatic spread involves the regional lymph nodes, lungs, and bone. (medscape.com)
  • Although it may be unusual for clinicians to encounter newly diagnosed patients with high-grade prostate cancer metastatic to the bone, researchers have noted an increase in patients presenting with high-risk disease since the US Preventive Services Task Force changed its recommendations on prostate cancer screenings, 1 noted Joseph F. Renzulli, II, MD, FACS . (onclive.com)
  • Bone morphogenic proteins (BMPs) are cytokines, that induce formation of bone. (lu.se)
  • The etiology of plasma cell neoplasms is unknown in the majority of cases. (medscape.com)
  • Depending on the apparent etiology, bone marrow biopsy may be needed. (medscape.com)
  • Herrera GA, Alexander CB, Jones M. Ultrastructural characterization of pulmonary neoplasms I. The role of electron microscopy in characterization of the most common epithelial neoplasms. (uab.edu)
  • Herrera GA, Alexander CB, Jones M. Ultrastructural characterization of pulmonary neoplasms II. (uab.edu)
  • Neoplasms present at the margins of resection have a poor prognosis. (elsevier.com)
  • Conventional segmental bone resection for paracortical osteosarcoma usually results in a large bone defect, requiring a large allograft, bone cement, or metal prosthesis to fill the defect and restore bone stability 3 . (researchsquare.com)
  • As a rule, bone scans are not useful in the workup of osteochondromas or in preoperative planning for resection. (medscape.com)
  • Published in an early online release of the ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE , "BONE MARROW SYNOPTIC REPORTING FOR HEMATOLOGIC NEOPLASMS" provides recommendations that-for the first time in an evidence-based model-help pathologists and laboratories consistently, accurately, and comprehensively report bone marrow findings directly relevant for patient outcomes. (medindia.net)
  • abstract = "Neoplasms of the supporting tissues in the head and neck are outnumbered by their histologic counterparts in the trunk and extremities. (elsevier.com)
  • Once known as myeloproliferative disorders (MPDs), myeloproliferative neoplasms were renamed and officially classified as cancers of the bone marrow in 2008 by the World Health Organization. (voicesofmpn.com)
  • A generalized lesion distribution, one that involves the entire skeletal system, is often associated with abnormalities that affect bone metabolism. (vin.com)
  • Antiresorptive drugs (ARD) are bone metabolism patients, resulting in increased bone density, reduced risk modulators widely used in patients with some physiological of fractures and improved quality of life of individuals4,5. (bvsalud.org)
  • Bone metabolism is dynamic, in concert with Wolff's law, and a normal subchondral bone plate displays the same capacity to increase in thickness according to physiologic loading [3]. (faoj.org)
  • We also observed impairment of hematopoietic stem cell self-renewal and fitness, as evidenced in noncompetitive and competitive bone marrow transplant experiments. (nih.gov)
  • The guideline is not intended to replace the CAP Cancer Protocol for bone marrow hematopoietic neoplasms, which remains a strong foundation for bone marrow reporting and provides guidance on additional important report components and attributes of specific hematopoietic neoplasms. (medindia.net)
  • Anemia results from bone marrow replacement by plasma cell myeloma and/or the loss of erythropoietin as a result of renal injury. (medscape.com)
  • Use additional code (U85) , if desired, to identify resistance, non-responsiveness and refractive properties of the neoplasm to antineoplastic drugs. (who.int)
  • Most develop in the bone marrow, the spongy interior of bones that contains immature stem cells. (mdanderson.org)
  • The cell becomes cancerous, begins multiplying rapidly and crowds out healthy cells in the blood and bone marrow. (mdanderson.org)
  • DUP-785 depleted UTP in bone marrow cells within 2 hr to 25% of control levels, after 4 days normal levels were found. (elsevier.com)
  • DHO-DH was measured in bone marrow cells and Colon 26 and 38 before and after treatment. (elsevier.com)
  • In bone marrow cells DHO-DH was also rapidly inhibited but recovered within 4 days. (elsevier.com)
  • This drug has also been shown to inhibit the adherence between bone marrow stroma and myeloma cells, to block apoptosis resistance, and to inhibit IL-6 induced proliferation and angiogenesis [ 1 , 2 ]. (cdlib.org)
  • Cancerous mutations tend to alter healthy cells in ways that help them survive conditions of inflammation in the bone marrow. (medindia.net)
  • In skeletally immature patients, the cells undergo enchondral bone formation (see the image below). (medscape.com)
  • PV is a myeloproliferative neoplasm (MPN) of the bone marrow characterized by an overproduction of erythrocytes and often other blood cells. (cdc.gov)
  • A neoplasm is an abnormal growth of cells that are produced when there is more cell division than normal or when cells do not die when they are supposed to. (voicesofmpn.com)
  • These gene mutations are thought to cause abnormal changes in the stem cells within the bone marrow, in turn affecting the number of blood cells produced. (voicesofmpn.com)
  • Generally, kidney tumours originate from the proliferation of malignant cells within the renal tubules (or nephrons), or they are neoplasms from the fibrous tissues (that cover the organ itself). (lugnani.com)
  • Normal plasma cells are found in the bone marrow and are an important part of the immune system. (invivoscribe.com)
  • Plasma cell neoplasms show a spectrum of disease from asymptomatic to symptomatic forms. (medscape.com)
  • Bone infarcts can be asymptomatic on presentation. (consultant360.com)
  • They are slow-growing neoplasms, usually asymptomatic, which can develop in compact or cancellous bone. (bvsalud.org)
  • You might be aware of that chordomas are rare, slowly growing, locally aggressive neoplasms of bone that arise from embryonic remnants of the notochord. (laparoscopyhospital.com)
  • Cancer that spreads to a bone can weaken the bone and increase your risk for fractures. (drugs.com)
  • The medullary infarcts, depending upon location can cause weakening of the underlying parent bone and lead to fractures. (consultant360.com)
  • Cancer that starts in a bone is uncommon. (medlineplus.gov)
  • Cancer that has spread to the bone from another part of the body is more common. (medlineplus.gov)
  • The most common symptom of bone cancer is pain. (medlineplus.gov)
  • Surgery is often the main treatment for bone cancer. (medlineplus.gov)
  • Because bone cancer can come back after treatment, regular follow-up visits are important. (medlineplus.gov)
  • What Is Bone Cancer? (medlineplus.gov)
  • What's New in Bone Cancer Research? (medlineplus.gov)
  • Smoking increases your risk for new or returning cancer, and can cause bone loss. (drugs.com)
  • We confirmed several known risk factors for thrombotic thrombocytopenia purpura and hemolytic uremic syndrome (cancer, bone marrow transplantation, pregnancy). (elsevier.com)
  • Uneétude descriptive, transversale portant sur les patientes traitées en radiothérapie à l'Hôpital Général de Douala pour cancer du col de l'utérus a été réalisée d'octobre 2020 à janvier 2021.Résultats. (bvsalud.org)
  • Ruxolitinib effectively controls the symptoms but does not offer a cure, as the malignant stem cell clone is located in the bone marrow and is generally not attacked. (ehealthweek2010.org)
  • MÉTODO: Se recolectaron datos radiográficos de 132 pacientes con patología tumoral confirmada mediante biopsia del servicio de tumores óseos del Hospital de Traumatología y Ortopedia Unidades Médicas de Alta Especialidad Dr. Victorio de la Fuente Narváez, Instituto Mexicano del Seguro Social, en Ciudad de México, durante el año 2019. (bvsalud.org)
  • A primary lesion of the bone is unlikely to affect multiple bones. (consultant360.com)
  • A useful step in establishing a differential diagnosis is to characterize a bone lesion as being aggressive or nonaggressive based on radiographic features (Table 2). (vin.com)
  • A generalized pattern may be considered aggressive if it is present in combination with other aggressive bone lesion features. (vin.com)
  • Osteoblastic activity at or near the lesion site results in a productive periosteal new bone response that will vary in appearance depending on the duration, extent of periosteal activity and the inciting insult. (vin.com)
  • Focal bone loss represents a well-margined, destructive lesion that may be surrounded by a rim of sclerotic reactive new bone suggesting slow or no lesion progression. (vin.com)
  • In certain bones, such as the pelvis and the scapula, computed tomography (CT) is a useful adjunct for localizing the lesion. (medscape.com)
  • The cartilage cap, which tops the lesion and can be quite thick in children, is replaced by enchondral bone formation in maturing patients. (medscape.com)
  • This lesion must be distinguished from a primary malignant fibrous histiocytoma of bone in view of the different prognostic implications. (elsevier.com)
  • This osteoarthritis is often accompanied by a coinciding bone marrow lesion (BML) which has been shown to result in poorer patient outcomes. (faoj.org)
  • Thromboembolic events (TE) are the most common complications of myeloproliferative neoplasms (MPN). (aacrjournals.org)
  • Increased and imbalanced dispersion of joint forces, combined with a concentration of stresses and synovial fluid infiltration into the subchondral bone, can lead to reduced healing capacity and abnormalities within the underlying cancellous bone. (faoj.org)
  • It presents images and information related to the morphology of normal blood and bone marrow (erythropoiesis, granulopoiesis, monocytic serie, lymphopoiesis, thrombopoiesis, and normal hemopoietic cel. (bvsalud.org)
  • BACKGROUND: Bone neoplasms require an adequate clinical-radiographic evaluation for their diagnosis. (bvsalud.org)
  • Bone Marrow Transplantation 2015;50(5):628-636. (aruplab.com)
  • A case report of aneurysmal bone cyst of the thoracic spine. (lww.com)
  • Patients and clinicians alike will benefit as the Pathology and Laboratory Quality Center (the Center) of the College of American Pathologists (CAP) releases a new evidence-based guideline that tackles the complexities of reporting findings from bone marrow specimens. (medindia.net)
  • McCarthy, EF & Dorfman, HD 1982, ' Chondrosarcoma of bone with dedifferentiation: A study of eighteen cases ', Human pathology , vol. 13, no. 1, pp. 36-40. (elsevier.com)
  • Results show the biologic effects of vinyl halide exposure to include changes in behavior, cardiovascular abnormalities, degenerative changes in the liver and bones, and the induction of malignant neoplasms, especially angiosarcomas of the liver. (cdc.gov)
  • For example, aggressive features are frequently associated with inflammatory and neoplastic bone disorders whereas non-aggressive features are often found with developmental and degenerative disease. (vin.com)
  • Bone contusions are poorly visualized on conventional radiographs and are unlikely to represent the diagnosis. (consultant360.com)